{
  "meta": {
    "title": "Hemostasis_And_Thrombosis",
    "url": "https://brainandscalpel.vercel.app/hemostasis-and-thrombosis-8f901832.html",
    "scrapedAt": "2025-12-01T04:07:50.918Z"
  },
  "questions": [
    {
      "text": "<p>A 68-year-old man is brought to the emergency department due to sudden-onset, severe right lower extremity pain.&nbsp; On physical examination, the right leg is pale and cold to the touch with absent distal pulses.&nbsp; Cardiac auscultation reveals an irregular tachycardia, and ECG shows atrial fibrillation.&nbsp; Right lower extremity ultrasonography reveals an arterial embolus.&nbsp; Intravenous heparin infusion is initiated.&nbsp; This medication is most likely to cause which of the following coagulation changes?</p>",
      "choices": [
        {
          "id": 1,
          "text": "No change\n\t\t\t\n\t\t\t\n\t\t\t\tProlonged\n\t\t\t\n\t\t\t\n\t\t\t\tDecreased"
        },
        {
          "id": 2,
          "text": "No change\n\t\t\t\n\t\t\t\n\t\t\t\tProlonged\n\t\t\t\n\t\t\t\n\t\t\t\tIncreased"
        },
        {
          "id": 3,
          "text": "Prolonged\n\t\t\t\n\t\t\t\n\t\t\t\tNo change\n\t\t\t\n\t\t\t\n\t\t\t\tIncreased"
        },
        {
          "id": 4,
          "text": "Prolonged\n\t\t\t\n\t\t\t\n\t\t\t\tProlonged\n\t\t\t\n\t\t\t\n\t\t\t\tNo change"
        },
        {
          "id": 5,
          "text": "Prolonged\n\t\t\t\n\t\t\t\n\t\t\t\tProlonged\n\t\t\t\n\t\t\t\n\t\t\t\tDecreased"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"672\" src=\"https://www.uworld.com/media/L4326.jpg\" ></p><p><strong>Heparin</strong> is an endogenous anticoagulant that exerts its effect <strong>indirectly</strong> by binding to <strong>antithrombin</strong>&nbsp;<strong>III</strong> (AT), a serine protease inhibitor that irreversibly neutralizes clotting factors.&nbsp; Heparin binding alters the shape of AT, which converts it from a <strong>slow to rapid inactivator</strong> of clotting factors and increases its activity <strong>&gt;1,000 fold</strong>.</p><p>Although AT neutralizes a number of clotting factors in the intrinsic pathway, its anticoagulant effect primarily stems from the inactivation of <strong>factor Xa</strong> and <strong>thrombin</strong>.&nbsp; Therefore, patients who receive heparin products typically have the following coagulation changes:</p><ul><li><p><strong>Prolonged thrombin time:</strong> Thrombin inactivation is strongest with unfractionated heparin infusion because the length of heparin chains in this formulation are longer, which inactivates thrombin more rapidly.&nbsp; Although low-molecular-weight heparin formulations contain shorter chain heparin molecules, they also inactivate thrombin but to a lesser extent.</p></li><li><p><strong>Decreased activity of factor Xa:</strong> All forms of heparin (eg, unfractionated, low molecular weight, fondaparinux) have strong activity against factor Xa.&nbsp; Antifactor Xa activity is usually monitored to determine when adequate anticoagulation is achieved.</p></li><li><p><strong>Prolonged partial thromboplastin time</strong> (PTT): Heparin primarily inhibits the intrinsic and final common clotting pathway; therefore, PTT is prolonged.</p></li></ul><p>Unlike heparin medications, which exert their anticoagulation effects broadly through the activation of AT, direct oral anticoagulants inhibit a single enzyme in the coagulation cascade, such as thrombin (eg, dabigatran) or factor Xa (eg, rivaroxaban).</p><p><strong>Educational objective:</strong><br>Heparin is an indirect anticoagulant that alters the shape of antithrombin (AT) III, thereby converting it from a slow to rapid inactivator of clotting factors.&nbsp; Because AT primarily neutralizes factor Xa and thrombin, patients on heparin have decreased factor Xa activity and prolonged thrombin time/partial thromboplastin time.&nbsp; In contrast, direct oral anticoagulants specifically target a single enzyme in the coagulation cascade, such as thrombin (eg, dabigatran) or factor Xa (eg, rivaroxaban).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17274",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 68-year-old man comes to the emergency department due to lightheadedness, generalized weakness, and palpitations.&nbsp; The patient has a prolonged history of hypertension and takes amlodipine.&nbsp; He does not use tobacco or alcohol.&nbsp; His blood pressure is 110/60 mm Hg and pulse is 144/min and irregular.&nbsp; ECG shows an irregularly irregular rhythm and absent P waves.&nbsp; The patient is started on beta blocker therapy for rate control, with improvement in his heart rate.&nbsp; Long-term anticoagulation is initiated to prevent atrial thrombus formation, and he is eventually discharged home on warfarin.&nbsp; Which of the following is the best test to monitor the anticoagulation effect of warfarin in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Activated partial thromboplastin time"
        },
        {
          "id": 2,
          "text": "Bleeding time"
        },
        {
          "id": 3,
          "text": "Fibrin split products"
        },
        {
          "id": 4,
          "text": "Fibrinogen levels"
        },
        {
          "id": 5,
          "text": "Prothrombin time"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"672\"  src=\"https://www.uworld.com/media/L4326.jpg\" draggable=\"false\" ></p><p>This patient&#39;s ECG (irregularly irregular rhythm with absent P waves) suggests <strong>atrial fibrillation (AF)</strong>, which alters cardiac flow dynamics, making thrombus formation more common.&nbsp; If this thrombus detaches from the atrial wall, there is a risk of stroke.&nbsp; The oral anticoagulant <strong>warfarin</strong> (Coumadin) reduces thrombus formation risk by inhibiting the activation of vitamin K-dependent clotting factors II, VII, IX, and X <strong>(vitamin K antagonist)</strong>.&nbsp; This leads to decreased levels of these factors, particularly <strong>factor VII</strong>, and therefore prolongs the <a href=\"466\">prothrombin time (PT)</a>.&nbsp; Another useful laboratory value is the <strong>International Normalized Ratio (INR)</strong>, a ratio of the patient&#39;s PT to a control (usual INR target for AF: 2.0-3.0).&nbsp; Examples of indications include AF, deep venous thrombosis, and pulmonary thromboembolism.&nbsp; Outpatients who take warfarin typically have their INR checked every few weeks (more frequently initially).</p><p>The most common side effect is excessive anticoagulation leading to bleeding (which can require vitamin K and fresh frozen plasma if rapid reversal is needed).&nbsp; Skin necrosis can occur during the first few days of treatment due to a transient hypercoagulable state (reduction in protein C anticoagulant activity before affecting other factors&#39; procoagulant activity); for this reason, heparin is typically administered temporarily at the start of warfarin therapy (&#x22;heparin bridge&#x22;).&nbsp; Warfarin should not be used during pregnancy because it is teratogenic and can cause fetal bleeding.</p><p><strong>(Choice A)</strong>&nbsp; Activated partial thromboplastin time (aPTT) is used to monitor unfractionated heparin, which primarily affects the intrinsic coagulation pathway.</p><p><strong>(Choice B)</strong>&nbsp; Bleeding time is used for the assessment of platelet function.&nbsp; Increased bleeding time can be seen with thrombocytopenia, von Willebrand disease, defects of platelet aggregation, disseminated intravascular coagulation (DIC), and aspirin therapy.</p><p><strong>(Choices C and D)</strong>&nbsp; The combination of a decreased fibrinogen level and the presence of fibrin split products (such as D-dimer) is characteristic of DIC.</p><p><strong>Educational objective:</strong><br>Warfarin is an oral anticoagulant that inhibits the carboxylation of vitamin K-dependent coagulation factors II, VII, IX, and X.&nbsp; It is used in atrial fibrillation, deep venous thrombosis, and pulmonary thromboembolism.&nbsp; Prothrombin time (PT)/International Normalized Ratio (INR) should be monitored regularly during treatment with warfarin.&nbsp; Activated partial thromboplastin time (aPTT) is used for monitoring unfractionated heparin.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1200",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 54-year-old man comes to the emergency department with pain and swelling in the right leg.&nbsp; The patient has no other medical problems and takes no medications.&nbsp; He has smoked a pack of cigarettes daily for the past 30 years.&nbsp; He is a business executive and just returned from an overseas trip.&nbsp; Physical examination shows pitting edema of the right leg and tenderness on deep palpation of the calf muscles.&nbsp; Peripheral pulses are symmetric and full.&nbsp; He is started on a medication that prolongs activated partial thromboplastin time and prothrombin time in a dose-dependent manner but has no effect on thrombin time.&nbsp; Which of the following agents was this patient most likely administered?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Cyclooxygenase inhibitor"
        },
        {
          "id": 2,
          "text": "Direct factor VIIa inhibitor"
        },
        {
          "id": 3,
          "text": "Direct factor Xa inhibitor"
        },
        {
          "id": 4,
          "text": "Direct thrombin inhibitor"
        },
        {
          "id": 5,
          "text": "Unfractionated heparin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"672\"  src=\"https://www.uworld.com/media/L4326.jpg\" draggable=\"false\" ></p><p>This patient has <strong>deep venous thrombosis</strong>, which is typically treated with <strong>anticoagulation therapy for <u>&gt;</u>3 months</strong> to prevent recurrent thrombosis.&nbsp; Initial treatment is often with <strong>heparin agents</strong> (eg, unfractionated heparin, low-molecular-weight heparin, fondaparinux), followed by bridging to an <strong>oral anticoagulant</strong> (most commonly warfarin).&nbsp; Additional treatment options include direct factor Xa inhibitors (eg, apixaban, rivaroxaban) and direct thrombin inhibitors (eg, dabigatran).</p><p>In general, medications that affect the extrinsic pathway prolong the prothrombin time (PT), whereas inhibition of the intrinsic pathway mainly prolongs the activated partial thromboplastin time (aPTT).&nbsp; The thrombin time (TT) is prolonged with medications that directly or indirectly inhibit thrombin.&nbsp; Because factor Xa is located at the junction of the <a href=\"466\">intrinsic and extrinsic pathways</a>, <strong>direct factor Xa inhibitors</strong> prolong both <strong>aPTT and PT</strong> with no effect on TT.</p><p><strong>(Choice A)</strong>&nbsp; Cyclooxygenase inhibitors (eg, aspirin) directly inhibit platelet activity and have little overall effect on aPTT, PT, or TT.</p><p><strong>(Choice B)</strong>&nbsp; Direct factor VIIa inhibitors are currently in development and work by inhibiting the extrinsic pathway of the coagulation cascade.&nbsp; Therefore, they would prolong PT with no effect on aPTT or TT.</p><p><strong>(Choice D)</strong>&nbsp; Direct thrombin inhibitors (eg, dabigatran) prevent the formation of thrombin (factor IIa), resulting in prolongation of aPTT, PT, and TT.</p><p><strong>(Choice E)</strong>&nbsp; <a href=\"1600\">Unfractionated heparin</a> binds to antithrombin and causes inactivation of several coagulation factors, most significantly thrombin and factor Xa.&nbsp; As a result, aPTT and TT will be prolonged.&nbsp; Although the PT should theoretically be prolonged by the action of heparin on the final common pathway, in practice, the PT reagent contains heparin neutralizers that minimize this effect.</p><p><strong>Educational objective:</strong><br>Direct factor Xa inhibitors (eg, apixaban, rivaroxaban) increase the prothrombin and activated partial thromboplastin times but do not affect the thrombin time.&nbsp; Unfractionated heparin and direct thrombin inhibitors (eg, dabigatran) prolong the thrombin time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "2133",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 72-year-old man comes to the emergency department due to increasing dyspnea on exertion.&nbsp; The patient has a history of severe aortic stenosis causing exertional dyspnea, but his symptoms have significantly worsened over the past several weeks.&nbsp; He also notes excessive fatigue and several occasions of black tarry stool.&nbsp; The patient has no history of a blood disorder or other chronic medical conditions.&nbsp; Physical examination shows a harsh systolic ejection murmur radiating to the neck.&nbsp; The abdomen is soft and nontender with no organomegaly.&nbsp; Testing of stool for occult blood is positive.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Hemoglobin</td><td>9.0 g/dL</td></tr><tr><td>Mean corpuscular volume</td><td>76 &micro;m<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>Platelets</td><td>380,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>PT</td><td>11 sec (INR 1.0)</td></tr><tr><td>Activated PTT</td><td>50 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Colonoscopy reveals scattered bleeding angiodysplasias in the right colon.&nbsp; Which of the following is most likely contributing to this patient&#39;s gastrointestinal bleeding?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Acquired von Willebrand factor deficiency"
        },
        {
          "id": 2,
          "text": "Decreased ADAMTS13 metalloprotease activity"
        },
        {
          "id": 3,
          "text": "Decreased hepatic synthesis of clotting factors"
        },
        {
          "id": 4,
          "text": "Formation of antiphospholipid antibodies"
        },
        {
          "id": 5,
          "text": "Uremic toxin&ndash;induced platelet dysfunction"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Aortic stenosis</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"2707\" src=\"https://www.uworld.com/media/highresdefault/L23798.png\"  ></p><p>This patient with <strong>severe aortic stenosis</strong> (AS) has symptomatic <strong>anemia</strong> (dyspnea, fatigue) with low mean corpuscular volume likely due to chronic bleeding from <strong>colonic angiodysplasias</strong>.&nbsp; Colonic, mucosal, and cutaneous bleeding is common in patients with severe AS due to <strong>acquired von Willebrand syndrome</strong>.</p><p>Von Willebrand factor (vWF) is a multimeric glycoprotein generated by endothelial cells and platelets.&nbsp; It plays 3 important roles in hemostasis:</p><ul><li><p>vWF binds to sites of endothelial injury and serves as a scaffold for platelet aggregation.</p></li><li><p>vWF promotes platelet aggregation at sites of high shearing pressure (often seen in areas of endothelial injury).</p></li><li><p>vWF acts as a carrier protein for factor VIII, which dramatically reduces the metabolism of factor VIII.</p></li></ul><p>The activity of vWF is greatest when it is in large, multimeric forms.&nbsp; However, large multimers of vWF are also most susceptible to unfolding in areas of <strong>high shear forces</strong>, exposing a cleavage site that makes them more vulnerable to destruction by the ADAMTS13 metalloproteinase.&nbsp; Because patients with severe AS typically have high shearing forces across the damaged valve, they have <strong>increased cleavage of vWF multimers</strong>, which eventually leads to vWF deficiency.&nbsp; Valve repair can reverse the bleeding diathesis.</p><p><strong>(Choice B)</strong>&nbsp; The activity of ADAMTS13 is elevated in patients with severe AS because vWF multimers become unfolded by the high shear stress, leading them to be more susceptible to metalloproteinase destruction.&nbsp; Decreased activity of ADAMTS13 is seen in thrombotic thrombocytopenic purpura, which is marked by microvascular thrombosis.</p><p><strong>(Choice C)</strong>&nbsp; Decreased hepatic synthesis of clotting factors can cause coagulopathy in patients with cirrhosis.&nbsp; Factor VIII levels are frequently low in patients with severe AS, which is due to increased destruction of vWF, not reduced hepatic synthesis.</p><p><strong>(Choice D)</strong>&nbsp; Acquired antiphospholipid antibody syndrome is seen primarily in those with systemic lupus erythematosus or other rheumatologic conditions.&nbsp; It is marked by arterial or venous thrombosis or pregnancy complications; bleeding diathesis is uncommon.</p><p><strong>(Choice E)</strong>&nbsp; Uremia reduces platelet adhesiveness and platelet aggregation, leading to an increased risk for bleeding.&nbsp; This patient has AS, not kidney disease.</p><p><strong>Educational objective:</strong><br>Patients with severe aortic stenosis are at high risk for mucocutaneous and colonic bleeding due to acquired von Willebrand deficiency.&nbsp; The von Willebrand factor multimers become unfolded by the high shear stress, leading to increased destruction by the ADAMTS13 metalloproteinase.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "19246",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 72-year-old woman comes to the office for a routine follow-up appointment.&nbsp; She has no symptoms and her past medical history is insignificant.&nbsp; Her temperature is 36.7 C (98 F), blood pressure is 110/80 mm Hg, and pulse is 76/min and irregular.&nbsp; ECG shows atrial fibrillation with no ischemic changes.&nbsp; Anticoagulation therapy with warfarin is initiated for stroke prevention.&nbsp; Two days later, the patient is hospitalized with severe skin and subcutaneous fat necrosis.&nbsp; Drug effects on which of the following processes are most likely responsible for this patient&#39;s skin findings?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Factor IX synthesis"
        },
        {
          "id": 2,
          "text": "Factor VIIa activity"
        },
        {
          "id": 3,
          "text": "Factor XIa activity"
        },
        {
          "id": 4,
          "text": "Fibrinogen conversion"
        },
        {
          "id": 5,
          "text": "Protein C activity"
        },
        {
          "id": 6,
          "text": "Prothrombin conversion"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This patient has <strong>warfarin-induced skin necrosis</strong>, a rare but important complication of warfarin initiation.&nbsp; It is thought to be due to a <strong>transient hypercoagulable state</strong> that can occur during the <strong>first few days</strong> of warfarin therapy.</p><p>The overall anticoagulant effect of <strong>warfarin</strong> is due primarily to its inhibition of the vitamin K-dependent gamma-carboxylation of clotting factors II, VII, IX, and X (&#x22;vitamin K-dependent clotting factors&#x22;).&nbsp; However, warfarin also decreases carboxylation of proteins C and S, which normally exert an anticoagulant effect (through proteolysis and deactivation of factors V and VIII).&nbsp; <strong>Protein C</strong> has a <strong>short half-life</strong>, so its anticoagulant activity is reduced quickly when warfarin therapy is initiated, by about 50% within the first day.&nbsp; During this time, the vitamin K-dependent clotting factors II, IX, and X continue to exert a procoagulant effect as they have longer half-lives (factor VII has a short half-life similar to protein C).</p><p>This difference in half-lives translates into a transient hypercoagulable state:</p><ul><li>Decreased protein C (anticoagulant) activity &#8594; procoagulant effect</li><li>Persistent clotting factor II, IX, and X activity &#8594; procoagulant effect</li></ul><p>Thrombosis and clot can interrupt blood flow to the skin and lead to skin necrosis.&nbsp; For this reason, overlapping coadministration of heparin <strong>(&#x22;heparin bridge&#x22;)</strong> is commonly used when warfarin is initiated.&nbsp; The risk of warfarin-induced skin necrosis is increased in patients with a preexisting protein C deficiency, as well as in those started on a large loading dose of warfarin.</p><p><strong>(Choice A)</strong>&nbsp; Warfarin affects coagulation factor carboxylation, not synthesis.</p><p><strong>(Choice B)</strong>&nbsp; Factor VII inhibition by warfarin has an anticoagulant effect.</p><p><strong>(Choice C)</strong>&nbsp; Warfarin does not have a major direct effect on factor XI activity that would cause skin necrosis.</p><p><strong>(Choices D and F)</strong>&nbsp; Fibrinogen and prothrombin activity may be impacted downstream, but this is not the primary process affected by warfarin.</p><p><strong>Educational objective:</strong><br>Warfarin inhibits proteins C and S (natural anticoagulants present in blood), which can lead to skin necrosis, particularly in patients with protein C or S deficiency.&nbsp; This complication is usually seen in the first few days of warfarin therapy.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1088",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 70-year-old man comes to the office due to palpitations.&nbsp; He has felt an irregular and fast heartbeat on multiple occasions over the last month.&nbsp; The patient has not had chest pain, dyspnea, dizziness, or weakness.&nbsp; His medical history includes hypertension and type 2 diabetes mellitus.&nbsp; Temperature is 36.7 C (98.1 F), pulse is 102/min and irregular, blood pressure is 140/82 mm Hg, and respirations are 16/min.&nbsp; Cardiopulmonary auscultation reveals clear lungs and no heart murmurs.&nbsp; ECG shows an irregularly irregular rhythm with absent P waves.&nbsp; The patient is started on metoprolol and apixaban.&nbsp; Which of the following is likely to be directly affected as the result of this therapy?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Conversion of factor X to Xa"
        },
        {
          "id": 2,
          "text": "Conversion of fibrinogen to fibrin"
        },
        {
          "id": 3,
          "text": "Conversion of plasminogen to plasmin"
        },
        {
          "id": 4,
          "text": "Conversion of prothrombin to thrombin"
        },
        {
          "id": 5,
          "text": "Gamma-carboxylation of coagulation factors"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Physiology > Hematology & Oncology > Atrial fibrillation</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"672\" src=\"https://www.uworld.com/media/L4326.jpg\" ></p><p>This patient has palpitations, an irregular pulse, and <a href=\"8818\">ECG findings</a> consistent with <strong>atrial fibrillation</strong>.&nbsp; Treatment with a rate control medication (eg, metoprolol) reduces atrioventricular conduction and limits ventricular tachycardia, which helps prevent symptoms (eg, palpitations, dizziness) and risk of cardiomyopathy.&nbsp; However, rate control agents do not inhibit uncoordinated atrial contraction, so patients remain at risk for atrial thrombus and embolic stroke.&nbsp; As a result, most patients are also initiated on <strong>anticoagulation</strong>.</p><p><strong>Direct factor Xa inhibitors</strong> (eg, apixaban) are often used for stroke prevention in atrial fibrillation as they are administered orally and do not require monitoring of drug levels (unlike warfarin).&nbsp; This class of medications blocks the active site of factor Xa, which prevents it from converting <strong>prothrombin to thrombin</strong>.&nbsp; Direct factor Xa inhibitors are denoted by names that end in &#x22;<strong>Xa</strong>-ban.&#x22;</p><p><strong>(Choice A)</strong>&nbsp; The conversion of factor X to factor Xa is the beginning the final common pathway of the <a href=\"4730\">coagulation cascade</a> and is triggered by factor VIIIa (intrinsic pathway) and tissue factor (extrinsic pathway).&nbsp; Factor Xa inhibitors block conversion of prothrombin to thrombin, not factor X to factor Xa.</p><p><strong>(Choice B)</strong>&nbsp; Factor Xa inhibitors reduce the conversion of fibrinogen to fibrin.&nbsp; However, this is a downstream (not direct) effect that occurs as a result of decreased thrombin levels.</p><p><strong>(Choice C)</strong>&nbsp; Tissue plasminogen activator is a fibrinolytic enzyme that increases the conversion of plasminogen to plasmin.&nbsp; It is primarily used to lyse ongoing clots in patients with acute ischemic strokes.</p><p><strong>(Choice E)</strong>&nbsp; Warfarin inhibits vitamin K epoxide reductase, which decreases the reduced form of vitamin K and limits gamma-carboxylation of vitamin K&ndash;dependent coagulation factors (II, VII, IX, X).</p><p><strong>Educational objective:</strong><br>Direct factor Xa inhibitors (eg, apixaban) are anticoagulants that block the active site of factor Xa, which leads to reduced conversion of prothrombin to thrombin.&nbsp; This class of medications is administered orally and requires no drug level monitoring.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13363",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 72-year-old woman is brought to the emergency department due to severe shortness of breath, tachypnea, and pleuritic-type chest pain.&nbsp; She had a similar episode 3 weeks ago and has been treated with warfarin since then.&nbsp; The patient has several other medical conditions and is taking all her medications as recommended.&nbsp; On examination, her temperature is 36.7 C (98 F), blood pressure is 120/60 mm Hg, pulse is 118/min, and respirations are 28/min.&nbsp; Pulse oximetry is 93% on room air.&nbsp; Laboratory results are notable for the following:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Coagulation studies</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Prothrombin time (PT)</td><td>18 sec</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;International Normalized Ratio (INR)</td><td>1.6</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>The patient&#39;s INR is subtherapeutic compared to her target INR range of 2.0-3.0 with warfarin.&nbsp; This patient is most likely taking which of the following additional medications?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Acetaminophen"
        },
        {
          "id": 2,
          "text": "Amiodarone"
        },
        {
          "id": 3,
          "text": "Aspirin"
        },
        {
          "id": 4,
          "text": "Cimetidine"
        },
        {
          "id": 5,
          "text": "Diazepam"
        },
        {
          "id": 6,
          "text": "Indomethacin"
        },
        {
          "id": 7,
          "text": "Metronidazole"
        },
        {
          "id": 8,
          "text": "Oxycodone"
        },
        {
          "id": 9,
          "text": "Phenytoin"
        }
      ],
      "correct_choice_id": 9,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t52323\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Drugs/supplements that affect warfarin metabolism (selected)</strong></p></td></tr><tr><td><p align=\"center\"><strong>CYP450<br><u>Inhibitors</u></strong></p><p align=\"center\"><strong>&#8593; Warfarin effect</strong></p><p align=\"center\">(&#8593; bleeding risk)</p></td><td><ul><li>Antibiotics (eg, metronidazole, macrolides)</li><li>Azole antifungals</li><li>Amiodarone</li><li>Cimetidine</li><li>Grapefruit juice</li></ul></td></tr><tr><td><p align=\"center\"><strong>CYP450<br><u>Inducers</u></strong></p><p align=\"center\"><strong>&#8595; Warfarin effect</strong></p><p align=\"center\">(&#8595; in efficacy)</p></td><td><ul><li>Carbamazepine</li><li>Phenytoin</li><li>Phenobarbital</li><li>Rifampin</li><li>St. John&#39;s wort</li></ul></td></tr><tr><td colspan=\"2\"><p><strong>CYP450</strong> = cytochrome P-450.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient with pleuritic chest pain, dyspnea, tachypnea, tachycardia, and hypoxia most likely experienced a <strong>recurrent pulmonary embolism</strong> (PE) in the setting of a <strong>subtherapeutic INR level</strong>, reflecting decreased warfarin efficacy.&nbsp; <strong>Warfarin</strong> is an oral anticoagulant that inhibits activation of vitamin K&ndash;dependent clotting factors, particularly factor VII.&nbsp; As a result, warfarin administration leads to prolongation of the prothrombin time (PT) and INR (ratio of a patient&#39;s PT compared to a normal control).&nbsp; In patients with atrial fibrillation, deep venous thrombosis, or PE who are taking warfarin for anticoagulation, the dose is usually adjusted to achieve a target therapeutic INR range (generally 2.0-3.0).</p><p>Precise dosing of warfarin can be difficult due to its many interactions with other drugs that affect cytochrome P-450 activity, plasma protein binding, and/or gastrointestinal absorption.&nbsp; Warfarin elimination occurs primarily through hepatic metabolism by cytochrome P-450 enzymes.&nbsp; Drugs that <strong>increase P-450 activity</strong>, such as <strong>phenytoin</strong>, phenobarbital, and rifampin, <strong>increase warfarin elimination</strong> and decrease its anticoagulant activity (reflected as a subtherapeutic INR &lt;2.0).&nbsp; Cholestyramine binds warfarin (and other drugs) in the intestine, thereby decreasing warfarin&#39;s therapeutic effect.</p><p><strong>(Choices A, C, and F)</strong>&nbsp; When used concurrently with warfarin, aspirin and other nonsteroidal anti-inflammatory drugs such as indomethacin increase the risk of bleeding due to antiplatelet effects and gastrointestinal ulceration.&nbsp; These drugs can also displace warfarin from plasma protein binding sites (increasing the concentration of free warfarin).&nbsp; Acetaminophen can interfere with vitamin K metabolism and enhance the effect of warfarin.</p><p><strong>(Choices B, D, and G)</strong>&nbsp; Both cimetidine and amiodarone inhibit the metabolism of warfarin, which can result in an increased PT/INR and bleeding risk.&nbsp; The interaction between amiodarone and warfarin is important because some patients with atrial fibrillation may be prescribed both medications.&nbsp; The commonly used antibiotics metronidazole and trimethoprim-sulfamethoxazole also inhibit warfarin metabolism.</p><p><strong>(Choices E and H)</strong>&nbsp; Benzodiazepines and opiates usually do not interact significantly with warfarin.</p><p><strong>Educational objective:</strong><br>Rifampin, phenobarbital, and phenytoin are potent enhancers of the cytochrome P-450 pathway; concurrent use of warfarin with these medications results in decreased efficacy of warfarin.&nbsp; In contrast, cimetidine, amiodarone, and trimethoprim-sulfamethoxazole inhibit warfarin metabolism, increasing the risk of bleeding.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1090",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 15-year-old boy is brought to the emergency department with fever, purulent nasal discharge, and epistaxis.&nbsp; The patient has had fever and persistent nasal discharge for the past 10 days.&nbsp; He developed intermittent epistaxis 2 days ago that has been difficult to control.&nbsp; The patient has also had easy bruising for the past 2 months.&nbsp; Medical history is significant for cystic fibrosis, and he has not been taking his prescribed medications.&nbsp; Results of coagulation studies are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Prothrombin time</td><td>25 sec</td></tr><tr><td>Partial thromboplastin time&nbsp;</td><td>35 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following coagulation factors is most likely to be abnormal in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Factor V"
        },
        {
          "id": 2,
          "text": "Factor VII"
        },
        {
          "id": 3,
          "text": "Factor VIII"
        },
        {
          "id": 4,
          "text": "Factor XII"
        },
        {
          "id": 5,
          "text": "Fibrinogen"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Vitamin k deficiency</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"466\" src=\"https://www.uworld.com/media/highresdefault/L9711.png\"  ></p><p>This patient with <strong>cystic fibrosis</strong> (CF) has bruising, epistaxis, and a prolonged PT, findings consistent with vitamin K deficiency.&nbsp; Patients with CF are at increased risk due to a predisposition to <strong>pancreatic insufficiency</strong>, in which viscous exocrine secretions block pancreatic ducts.&nbsp; Reduced secretion of pancreatic enzymes leads to <strong>fat malabsorption</strong> and deficiency of fat-soluble vitamins (ie, A, D, E, K).</p><p>Vitamin K normally acts as an important cofactor in the <a href=\"35655\">hepatic activation</a> of coagulation <strong>factors II, VII, IX, and X</strong>, as well as proteins C and S.&nbsp; <strong>Vitamin K deficiency</strong> results in low levels of activated vitamin K&ndash;dependent coagulation factors, and <strong>prolonged PT</strong> is caused by deficiency of activated factor VII.&nbsp; Activated PTT (aPTT) is typically normal, as seen in this patient, although it can be prolonged with severe vitamin K deficiency (due to the effect on factor II).</p><p>Vitamin K deficiency presents with <strong>easy bruising</strong> and mucosal bleeding (eg, <strong>epistaxis</strong>).&nbsp; Treatment is vitamin K administration, and patients with CF also should receive pancreatic enzyme replacement therapy to improve fat-soluble vitamin absorption.</p><p><strong>(Choice A)</strong>&nbsp; Factor V is not dependent on vitamin K for activation.&nbsp; Factor V deficiency is rare and leads to prolonged PT and aPTT.</p><p><strong>(Choice C)</strong>&nbsp; Hemophilia A is an X-linked recessive disorder caused by factor VIII deficiency.&nbsp; As part of the intrinsic pathway, factor VIII deficiency results in prolongation of aPTT with normal PT.</p><p><strong>(Choice D)</strong>&nbsp; Factor XII (ie, Hageman factor) is part of the intrinsic coagulation pathway and is not vitamin K dependent.&nbsp; Patients with inherited factor XII deficiency are typically asymptomatic but have prolonged aPTT.</p><p><strong>(Choice E)</strong>&nbsp; Fibrinogen normally assists in coagulation via the final common pathway through fibrin clot formation and platelet binding.&nbsp; Fibrinogen is not dependent on vitamin K for activation.&nbsp; Coagulation disorders involving fibrinogen include severe liver disease and disseminated intravascular coagulation, which are associated with prolonged PT and aPTT.</p><p><strong>Educational objective:</strong><br>Patients with cystic fibrosis are at risk for fat-soluble vitamin (ie, A, D, E, K) deficiency due to fat malabsorption from pancreatic insufficiency.&nbsp; Vitamin K is an important cofactor in the activation of coagulation factors II, VII, IX, and X.&nbsp; Vitamin K deficiency leads to easy bruising, mucosal bleeding, and prolonged PT.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "18882",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 45-year-old-woman comes to the office for follow-up 2 weeks after hospitalization for acute pyelonephritis.&nbsp; The patient was treated with morphine for pain and a course of broad-spectrum antibiotics, which she has completed.&nbsp; Her symptoms have now resolved.&nbsp; The patient also has a history of mechanical mitral valve replacement and takes warfarin.&nbsp; Physical examination shows no new findings.&nbsp; Her INR was 2.5 at the time of hospital discharge but is 6.2 today despite no change to warfarin dosage.&nbsp; Which of the following best explains the laboratory findings in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Decreased production of thromboxane A2"
        },
        {
          "id": 2,
          "text": "Disruption of intestinal bacterial flora"
        },
        {
          "id": 3,
          "text": "Formation of anticlotting factor antibodies"
        },
        {
          "id": 4,
          "text": "Increased cytochrome P-450 activity"
        },
        {
          "id": 5,
          "text": "Increased dietary vitamin K absorption"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Warfarin</strong> is a vitamin K antagonist that inhibits epoxide reductase in the liver, thereby preventing gamma carboxylation of vitamin K&ndash;dependent clotting factors (II, VII, IX, X).&nbsp; This creates an anticoagulant state that is reflected on laboratory assessment as a prolonged INR.&nbsp; Because the effect of warfarin is significantly altered by certain foods and medications, patients on long-term warfarin are at risk for subtherapeutic or <strong>supratherapeutic INR</strong> due to any of the following:</p><ul><li><p>Change in dietary vitamin K intake: Increase in dietary vitamin K increases the availability of vitamin K in the liver, which counters the inhibitory effect of warfarin on epoxide reductase.&nbsp; Therefore, patients on warfarin are advised to eat a consistent amount of vitamin K&ndash;containing foods (eg, leafy greens, brussels sprouts).</p></li><li><p><strong>Disruption to intestinal flora:</strong> Intestinal flora produce vitamin K as a byproduct of metabolism.&nbsp; Therefore, antibiotics that target gram-negative bacteria such as metronidazole, macrolides, and fluroquinolones can cause supratherapeutic INR due to destruction of vitamin K&ndash;producing bacteria in the gut.&nbsp; In this patient, the <strong>administration of an antibiotic</strong> (eg, ciprofloxacin) for pyelonephritis likely destroyed gram-negative bacteria in her gut, thereby <strong>reducing vitamin K production</strong> and causing a supratherapeutic INR.</p></li><li><p>Alteration to cytochrome P450 2C9 activity: Several medications induce or inhibit cytochrome P450 2C9, which alters the speed of warfarin metabolism.&nbsp; For instance, phenytoin, carbamazepine, and rifampin increase&nbsp;cytochrome P450 2C9 activity, which can result in a subtherapeutic INR <strong>(Choice D)</strong>.&nbsp; In contrast, metronidazole, fluconazole, and amiodarone inhibit cytochrome P450 2C9 activity, which can result in a supratherapeutic INR.</p></li></ul><p><strong>(Choice A)</strong>&nbsp; Aspirin exerts an anticoagulation effect by inhibiting the release of thromboxane A2 by platelets, which subsequently reduces platelet aggregation.&nbsp; This can lead to prolonged bleeding time but does not increase INR.</p><p><strong>(Choice C)</strong>&nbsp; Anticlotting factor antibodies can occasionally occur due to recent pregnancy, malignancy, or rheumatologic disease.&nbsp; Most cases involve inhibition of factor VIII, which leads to a bleeding diathesis and prolonged aPTT (not INR, which reflects PT).&nbsp; This patient with a recent infection treated with antibiotics is more likely to have supratherapeutic INR due to disruption of vitamin K production by intestinal flora.</p><p><strong>(Choice E)</strong>&nbsp; Increased dietary vitamin K leads to a subtherapeutic INR due to increased vitamin K availability in the liver.</p><p><strong>Educational objective:</strong><br>Patients on warfarin who take antibiotics that target gram-negative microorganisms (eg, metronidazole, macrolides, fluroquinolones) can develop supratherapeutic INR due to disruption of vitamin K&ndash;producing intestinal flora.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17237",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 12-year-old boy experiences excessive bleeding following a tooth extraction.&nbsp; His past medical history includes episodes of painful joint swelling from minor trauma.&nbsp; Physical examination shows a soft and nontender abdomen with a liver span of 10 cm.&nbsp; The spleen is not palpable.&nbsp; Laboratory results are as follows:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Bleeding time</td><td>5 min</td></tr><tr><td>Activated partial thromboplastin time</td><td>25 sec</td></tr><tr><td>Prothrombin time</td><td>23 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>This patient most likely has a deficiency involving which of the following factors?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Factor VII"
        },
        {
          "id": 2,
          "text": "Factor VIII"
        },
        {
          "id": 3,
          "text": "Factor XI"
        },
        {
          "id": 4,
          "text": "Hageman factor"
        },
        {
          "id": 5,
          "text": "von Willebrand factor"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Coagulopathy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"466\"  src=\"https://www.uworld.com/media/L9711.jpg\" draggable=\"false\" ></p><p>This patient&#39;s hemarthroses and excessive bleeding following tooth extraction are suggestive of a coagulopathy (ie, clotting factor deficiency).&nbsp; <strong>Coagulopathies</strong> generally present with <strong>deep-tissue bleeding</strong> into joints, muscles, and subcutaneous tissue.&nbsp; In contrast, <strong>platelet defects</strong> typically manifest with <strong>mucocutaneous bleeding</strong> (eg, epistaxis, petechiae).&nbsp; The patient&#39;s laboratory results show a normal bleeding time, normal activated partial thromboplastin time (aPTT), and a prolonged prothrombin time (PT).&nbsp; The normal bleeding time indicates adequate platelet function, and the normal aPTT indicates an intact intrinsic coagulation system.&nbsp; However, the <strong>prolonged PT</strong> indicates a defect in the <strong>extrinsic</strong> coagulation pathway.&nbsp; Therefore, the patient is most likely deficient in factor VII.</p><p><strong>(Choice B)</strong>&nbsp; Factor VIII deficiency results in classic X-linked hemophilia A.&nbsp; Coagulation studies will show a normal bleeding time, normal PT, and prolonged aPTT.</p><p><strong>(Choice C)</strong>&nbsp; Factor XI deficiency results in a rare autosomal recessive disorder called hemophilia C.&nbsp; Spontaneous bleeding is rare in this condition, but affected patients are at increased risk for bleeding following surgery or trauma.&nbsp; Coagulation studies will show a prolonged aPTT and normal PT.</p><p><strong>(Choice D)</strong>&nbsp; Hageman factor (factor XII) deficiency is an autosomal recessive disorder that does not typically cause clinically significant bleeding despite aPTT prolongation.</p><p><strong>(Choice E)</strong>&nbsp; von Willebrand factor (vWF) functions as both a carrier molecule for factor VIII (protecting it from being degraded) and as a mediator of platelet adhesion to the endothelium.&nbsp; It presents with prolonged bleeding time and normal/prolonged aPTT.</p><p><strong>Educational objective:</strong><br>A normal bleeding time indicates adequate platelet hemostatic function.&nbsp; A normal activated partial thromboplastin time (aPTT) indicates an intact intrinsic coagulation system.&nbsp; Prolonged prothrombin time in the setting of normal aPTT indicates a defect in the extrinsic coagulation system at a step that is not shared with the intrinsic system.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1903",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 25-year-old woman is brought to the emergency department after a motor vehicle collision.&nbsp; She has a pneumothorax, multiple rib fractures, and a right femur and tibial fracture.&nbsp; A chest tube is placed.&nbsp; The patient receives resuscitation and undergoes repair of the femur and tibial fractures.&nbsp; The following day, she develops respiratory distress, decreased urine output, and persistent bleeding from the chest tube drains and around the intravenous lines.&nbsp; Which of the following sets of laboratory findings is most likely to be seen in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;"
        },
        {
          "id": 2,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        },
        {
          "id": 3,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        },
        {
          "id": 4,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;"
        },
        {
          "id": 5,
          "text": "&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > DIC</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"24482\" src=\"https://www.uworld.com/media/L50403.jpg\" ></p><p>This patient with multiple injuries following a severe motor vehicle accident developed respiratory distress, reduced renal output, and oozing from the catheter and venipuncture sites.&nbsp; This presentation raises strong suspicion for <strong>disseminated intravascular coagulation</strong> (DIC), a consumptive coagulopathy associated with <strong>trauma</strong>, sepsis, malignancy, and obstetrical complications.</p><p>In DIC due to trauma, the coagulation cascade is triggered by damage to the vascular endothelium (exposes tissue factor) and tissues (releases procoagulant proteins and phospholipids).&nbsp; This leads to the generation of fibrin- and platelet-rich <strong>microvascular thrombi</strong>, which consumes platelets, coagulation factors (eg, <strong>low factor VII</strong>), and fibrinogen.&nbsp; Fibrinolysis and anticoagulant proteins then dissolve the clots, which <strong>depletes protein C</strong>, protein S, and antithrombin.</p><p>Most patients with acute DIC develop <strong>bleeding complications</strong> such as <strong>oozing from catheters/venipuncture sites</strong>, ecchymosis, and petechiae.&nbsp; End organ damage to the kidneys (eg, renal insufficiency) and lungs (eg, pulmonary hemorrhage) is common.&nbsp; Many patients also have microangiopathic hemolytic anemia (eg, schistocytes) due to shearing of red blood cells by intravascular thrombi.</p><p><strong>Educational objective:</strong><br>Acute disseminated intravascular coagulation is a consumptive coagulopathy linked to severe trauma.&nbsp; Widespread formation of microvascular thrombi leads to consumption of platelets, coagulation factors, and fibrinogen.&nbsp; Subsequent activation of anticoagulant proteins leads to low protein C/S; fibrinolysis elevates D-dimer.&nbsp; Most patients have bleeding complications (eg, oozing from venipuncture/catheter sites) and end organ damage to the lungs or kidneys.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "15017",
      "difficulty": "N/A"
    },
    {
      "text": "A 44-year-old male is hospitalized with unstable angina.&nbsp; On the fourth day of hospitalization he develops severe foot pain and right toe paleness.&nbsp; His laboratory testing is significant for platelet count of 60,000/mm<SUP>3</SUP>.&nbsp; Treatment with argatroban is initiated immediately.&nbsp; The drug (argatroban) used to treat this patient's current condition has which mechanism of action?",
      "choices": [
        {
          "id": 1,
          "text": "Binds to the thrombin active site"
        },
        {
          "id": 2,
          "text": "Blocks glutamate residue carboxylation"
        },
        {
          "id": 3,
          "text": "Block ADP receptors"
        },
        {
          "id": 4,
          "text": "Block GP IIb/IIIa surface receptors"
        },
        {
          "id": 5,
          "text": "Inhibits phosphodiesterase"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><P>Heparin is the most important cause of thrombocytopenia in hospitalized patients.&nbsp; Occurrence of heparin-induced thrombocytopenia (HIT) is much more common with the use of unfractionated heparin compared to low molecular weight heparin.&nbsp; HIT more commonly leads to paradoxical thrombosis rather than bleeding.&nbsp; HIT is a serious disorder caused by antibodies to heparin and platelet factor IV.</P><P>Direct thrombin inhibitors (hirudin, lepirudin and argatroban) do not require antithrombin-III for their action and are drugs of choice in the treatment of HIT.&nbsp; Patients with HIT need ongoing anticoagulation due to the presence of, or possibility of thrombosis.&nbsp; Upon clinical suspicion of HIT, the most important initial step in treatment is to stop all forms of heparin.</P><P><STRONG>(Choice B)</STRONG> Warfarin inhibits vitamin K dependent &#x3B3;-carboxylation of glutamic acid residues of clotting factors II, VII, IX and X.</P><P><STRONG>(Choices C, D and E)</STRONG> Platelet plug formation involves three critical steps: adhesion, aggregation and release (see diagram).&nbsp; Drugs that inhibit platelet aggregation work by different mechanisms.</P><BLOCKQUOTE dir=ltr><P><img id=\"9085\"  src=\"https://www.uworld.com/media/Anticoagulants3.gif\" draggable=\"false\" ></P></BLOCKQUOTE><P>Aspirin irreversibly acetylates platelet cyclooxygenase-I leading to decreased formation of thromboxane A2. &nbsp;Aspirin is used for primary and secondary prevention of myocardial infarction and strokes.&nbsp;</P><P>Ticlopidine and clopidogrel inhibit ADP mediated platelet aggregation.&nbsp; They are useful following percutaneous coronary intervention (PCI), and for treatment of unstable angina and non-Q wave myocardial infarction.</P><P>Dipyridamole and cilostazol inhibit platelet aggregation by inhibiting phosphodiesterase activity and increasing cAMP.&nbsp;</P><P>Glycoprotein IIb/IIIa inhibitors inhibit binding of platelet glycoprotein IIb/IIIa with fibrinogen and fibronectin. &nbsp;The glycoprotein IIb/IIIa inhibitors abciximab, eptifibatide and tirofiban are approved for use following percutaneous intervention (PCI) in acute coronary syndrome.</P><P><STRONG>Educational objective:</STRONG><BR>Heparin-induced thrombocytopenia (HIT) is treated with direct thrombin inhibitors (DTIs) such as argatroban.&nbsp; Both high molecular weight heparin and LMWH should be avoided in these patients.</P>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1078",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 36-year-old woman with mitral valve prolapse comes to the office due to dyspnea and is found to have severe mitral valve regurgitation.&nbsp; Two weeks later, the patient undergoes elective mechanical mitral valve replacement.&nbsp; Continuous heparin infusion and oral warfarin are initiated following the procedure.&nbsp; Coagulation studies during admission are as follows:</p><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td><strong>Postoperative day</strong></td><td><strong>1</strong></td><td><strong>2</strong></td><td><strong>3</strong></td><td><strong>4</strong></td></tr><tr><td><strong>INR</strong></td><td>1.1</td><td>1.5</td><td>1.8</td><td>2.1</td></tr><tr><td><strong>PTT(seconds)</strong></td><td>72</td><td>76</td><td>74</td><td>78</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>&nbsp;<p>The patient achieves the goal of INR &#8805;2.5 on postoperative day 5 and heparin infusion is discontinued.&nbsp; Which of the following likely caused the delay in achieving therapeutic INR in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Clotting factors generated before warfarin initiation"
        },
        {
          "id": 2,
          "text": "Formation of anti-platelet factor 4/heparin antibodies"
        },
        {
          "id": 3,
          "text": "High total body stores of vitamin K"
        },
        {
          "id": 4,
          "text": "Induction of an enzyme that metabolizes warfarin"
        },
        {
          "id": 5,
          "text": "Slow onset of steady-state drug concentration"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"3270\" src=\"https://www.uworld.com/media/L24827.jpg\" ></p><p><strong>Warfarin</strong> is a vitamin K antagonist that blocks <strong>epoxide reductase</strong> in the liver, leading to impaired vitamin K recycling.&nbsp; This depletes the reduced form of vitamin K, which is required for gamma carboxylation of <strong>vitamin K&ndash;dependent clotting factors</strong> (II, VII, IX, and X).&nbsp; In the absence of gamma carboxylation, vitamin K&ndash;dependent clotting factors cannot bind calcium or phospholipid membranes to induce coagulation.</p><p>Because warfarin inhibits gamma carboxylation of <strong>new</strong> vitamin K&ndash;dependent clotting factors, therapeutic efficacy is delayed until <strong>preexisting clotting factors</strong> in the plasma are consumed.&nbsp; Although INR tends to slowly increase in the first few days of administration due to the short half-life of factor VII (4-6 hours), full <strong>therapeutic effect</strong> does not typically occur for <strong>3 days</strong> due to the long half-life of <strong>factor II</strong>.</p><p>Warfarin also inhibits gamma carboxylation of the proteins C and S.&nbsp; Because these proteins exert an anticoagulant effect, the initiation of warfarin can be associated with an initial procoagulant state.&nbsp; However, once preexisting vitamin K&ndash;dependent clotting factors are consumed, an anticoagulant effect is established.</p><p><strong>(Choice B)</strong>&nbsp; Anti-platelet factor 4/heparin antibodies cause heparin-induced thrombocytopenia, which typically arise 5-10 days after heparin initiation.&nbsp; This condition is marked by thrombocytopenia and a high risk of arterial and venous thrombosis,&nbsp;but would&nbsp;not result in a delay in therapeutic INR following warfarin administration.</p><p><strong>(Choice C)</strong>&nbsp; Total body vitamin K is sufficient for several weeks; it does not contribute to a delay in warfarin efficacy.&nbsp; However, increased intake of foods rich in vitamin K (eg, green leafy vegetables) can lead to subtherapeutic INR due to increased vitamin K availability in the liver.</p><p><strong>(Choice D)</strong>&nbsp; Warfarin is metabolized by the hepatic cytochrome P450 2C9 enzyme.&nbsp; Because many other medications induce or inhibit this enzyme, warfarin is susceptible to a wide range of drug interactions.&nbsp; However, the delay in achieving therapeutic INR is primarily due to the presence of preexisting clotting factors.</p><p><strong>(Choice E)</strong>&nbsp; Warfarin reaches maximal plasma concentration approximately 90 minutes after administration.&nbsp; The delay in efficacy is due to the presence of preexisting clotting factors.</p><p><strong>Educational objective:</strong><br>Warfarin blocks epoxide reductase, which lowers the reduced form of vitamin K in the liver; this prevents gamma carboxylation of vitamin K&ndash;dependent clotting factors (II, VII, IX, and X).&nbsp; Because warfarin only blocks the generation of new clotting factors, therapeutic effect is delayed 3-5 days until preexisting clotting factors are consumed.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17236",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 26-year-old woman is found to have a single amino acid substitution (glutamine for arginine) near the protein C cleavage site in her coagulation factor V gene product.&nbsp; The patient is at greatest risk for developing which of the following conditions?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Petechiae and ecchymoses"
        },
        {
          "id": 2,
          "text": "Recurrent hemarthroses"
        },
        {
          "id": 3,
          "text": "Renal artery stenosis"
        },
        {
          "id": 4,
          "text": "Splenic infarction"
        },
        {
          "id": 5,
          "text": "Pulmonary thromboembolism"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Inherited thrombophilia</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>The major clinical manifestations of factor V Leiden include deep vein thrombosis (DVT), cerebral vein thrombosis, and recurrent pregnancy loss.&nbsp; Because pulmonary thromboembolism occurs in approximately 50% of all individuals with untreated DVTs, the young woman presented here is at significant risk of developing a pulmonary thromboembolism at some point in her lifetime.</p><p>Factor V Leiden is a common cause of inherited thrombophilia.&nbsp; Heterozygote carriers of factor V Leiden have five to ten times the risk of developing a thrombosis, while homozygote carriers of factor V Leiden have fifty to one hundred times the risk of developing a thrombosis.</p><p>Factor V Leiden causes thrombophilia through two pathophysiological mechanisms.&nbsp; In normal hemostasis, activated protein C (APC) restricts clot formation by proteolytically inactivating factors Va and VIIIa.&nbsp; Factor Va Leiden has reduced susceptibility to cleavage by APC, however.&nbsp; Because factor Va is a cofactor in the conversion of prothrombin to thrombin, persistently circulating factor Va Leiden results in increased thrombin production.&nbsp; Additionally, factor V Leiden is unable to support APC anticoagulant activity.&nbsp; This combination of increased coagulation and decreased anticoagulation produces the hypercoagulable state seen in those with factor V Leiden.</p><p><b>(Choice A) </b>Petechiae and ecchymoses are more consistent with qualitative or quantitative platelet abnormalities than factor V Leiden.</p><p><b>(Choice B) </b>Recurrent hemarthroses are suggestive of hemophilia (factor VIII or IX deficiency), not factor V Leiden.</p><p><b>(Choice C) </b>Renal artery stenosis is primarily caused by atherosclerosis and fibromuscular disease, not thrombosis.&nbsp; Moreover, factor V Leiden is associated with an increased risk of deep venous (not arterial) thrombosis.<b> </b></p><p><b>(Choice D) </b>Major causes of splenic infarction include sickle cell anemia, infectious endocarditis, and myeloproliferative disorders.&nbsp; Moreover, the factor V Leiden mutation is associated with deep venous (not arterial) thrombosis.</p><p><b>Educational Objective: </b><br>Heterozygote carriers of a mutation in factor V Leiden, which is modified to resist activated protein C, have a hypercoagulable state that predisposes to deep vein thromboses (the source of most pulmonary emboli).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1879",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 54-year-old man comes to the office due to 2 days of redness and pain in his right arm.&nbsp; He was recently diagnosed with superficial thrombophlebitis involving the left lower and upper extremities.&nbsp; His symptoms then subsided within days of nonsteroidal anti-inflammatory drug therapy only.&nbsp; The patient has no other past medical history.&nbsp; He has some abdominal discomfort that he attributes to gastroesophageal reflux disease.&nbsp; Temperature is 37.6 C (99.7 F).&nbsp; On examination, there is erythema and tenderness extending linearly from the right forearm to just anterior to the right antecubital fossa.&nbsp; No fluid collection is palpable.&nbsp; Complete blood count shows mild leukocytosis.&nbsp; The patient&#39;s symptoms may indicate the presence of which of the following?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Celiac sprue"
        },
        {
          "id": 2,
          "text": "Chlamydial infection"
        },
        {
          "id": 3,
          "text": "Hyperthyroidism"
        },
        {
          "id": 4,
          "text": "Polycystic kidneys"
        },
        {
          "id": 5,
          "text": "Visceral cancer"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Thrombophlebitis</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Migratory thrombophlebitis</strong> should raise suspicion for <strong>cancer</strong>.&nbsp; Hypercoagulability is a very common paraneoplastic syndrome seen most frequently in <strong>visceral</strong> adenocarcinomas of the <strong>pancreas</strong>, colon, and lung.&nbsp; <strong>Hypercoagulability</strong> develops because adenocarcinomas produce a thromboplastin-like substance capable of causing chronic intravascular coagulations that can disseminate and tend to migrate.</p><p>Migratory superficial thrombophlebitis, known as <strong>Trousseau syndrome</strong>, is named after Armand Trousseau, a well-respected French physician who first described the association with cancer.&nbsp; Trousseau later diagnosed his own visceral cancer after developing the syndrome.</p><p>Trousseau also described the Trousseau sign (hand/forearm muscle spasms on sphygmomanometric measurement) associated with hypocalcemia.</p><p><strong>(Choice A)</strong>&nbsp; Celiac sprue has been associated with a hemorrhagic diathesis (rather than abnormal thrombosis).&nbsp; The malabsorption resulting from celiac sprue can result in vitamin K deficiency.</p><p><strong>(Choices B and D)</strong>&nbsp; Polycystic kidney disease is not among the conditions commonly associated with an acquired prothrombotic state.&nbsp; Disseminated chlamydia infections are classically associated with reactive arthritis (not thrombophlebitis), and infections in general can create a systemic inflammatory state that favors thrombosis.&nbsp; However, malignancy would be a more likely explanation for migratory superficial thrombophlebitis accompanied by vague abdominal pain.</p><p><strong>(Choice C)</strong>&nbsp; Hyperthyroidism has been associated with a hypercoagulable state and is occasionally reported in cases of cerebral venous thrombosis, but there is no evidence of a significant association with venous thrombotic events.</p><p><strong>Educational objective:</strong><br>A paraneoplastic syndrome of hypercoagulability may be seen in some patients with cancer, especially adenocarcinomas of the pancreas, colon, or lung.&nbsp; Superficial venous thromboses may therefore appear in one site and then resolve, only to recur in another site.&nbsp; This is known as Trousseau syndrome (migratory superficial thrombophlebitis), an indication of visceral cancer.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "475",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 78-year-old man is found unresponsive and is brought by ambulance to the emergency department.&nbsp; Upon arrival, the family says he has a complicated medical history and takes multiple medications but has no known drug allergies.&nbsp; Noncontrast CT scan of the head reveals intracranial hemorrhage.&nbsp; The patient is given a recombinant biologic agent that has antigen homology with factor Xa but no catalytic effect.&nbsp; The agent is most likely to antagonize the effects of which of the following drugs?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Apixaban"
        },
        {
          "id": 2,
          "text": "Aspirin"
        },
        {
          "id": 3,
          "text": "Dabigatran"
        },
        {
          "id": 4,
          "text": "Ticagrelor"
        },
        {
          "id": 5,
          "text": "Warfarin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t58955\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Anticoagulation reversal for life-threatening bleeding</strong></p></td></tr><tr><td><p align=\"center\"><strong>Drug</strong></p></td><td><p align=\"center\"><strong>Mechanism of action</strong></p></td><td><p align=\"center\"><strong>Reversal</strong></p></td></tr><tr><td><p align=\"center\"><strong>Warfarin</strong></p></td><td><ul><li>&darr; Production of vitamin&nbsp;K&ndash;dependent clotting factors</li></ul></td><td><ul><li>PCC</li><li>Intravenous vitamin&nbsp;K</li></ul></td></tr><tr><td><p align=\"center\"><strong>Dabigatran</strong></p></td><td><ul><li>Direct inhibition of clot-bound and free thrombin</li></ul></td><td><ul><li>Idarucizumab (mAb fragment that binds dabigatran)</li><li>PCC</li></ul></td></tr><tr><td><p align=\"center\"><strong>Factor Xa inhibitors</strong><br />(eg,&nbsp;rivaroxaban, apixaban)</p></td><td><ul><li>Direct inhibition of factor&nbsp;Xa</li></ul></td><td><ul><li>Recombinant modified factor Xa (eg,&nbsp;andexanet)</li><li>PCC</li></ul></td></tr><tr><td><p align=\"center\"><strong>Heparin</strong></p></td><td><ul><li>&uarr; Activity of antithrombin&nbsp;III</li></ul></td><td><ul><li>Protamine sulfate</li></ul></td></tr><tr><td colspan=\"3\"><p><strong>mAb</strong> = monoclonal antibody;<strong> PCC</strong> = prothrombin complex concentrate (contains vitamin K&ndash;dependent clotting factors).</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient&#39;s intracranial hemorrhage was likely treated with <strong>andexanet alfa</strong>, a biologic agent that shares homology with factor Xa but has no proteolytic effect.&nbsp; It is administered to patients who have <strong>life-threatening bleeding</strong> while on a factor Xa inhibitor (eg, rivaroxaban, <strong>apixaban</strong>).&nbsp; The similarity of andexanet&nbsp;to factor Xa&nbsp;allows&nbsp;it to function&nbsp;as a <strong>decoy</strong> that binds to factor Xa inhibitors.&nbsp; This restores intravascular coagulation by increasing the availability of endogenous factor Xa, which converts prothrombin to thrombin and generates fibrin clots.&nbsp; Andexanet is reserved for life-threatening bleeding because it is associated with a significant risk of thrombosis.</p><p><strong>(Choice B)</strong>&nbsp; Aspirin inhibits cyclooxygenase, which prevents platelet aggregation by blocking the generation of thromboxane A2.&nbsp; There is no reversal agent for aspirin widely available.&nbsp; Aspirin does not target factor Xa.</p><p><strong>(Choice C)</strong>&nbsp; Dabigatran is a direct oral anticoagulant (DOAC) that inhibits circulating and clot-bound thrombin.&nbsp; It is reversed by idarucizumab, a monoclonal antibody fragment that binds to and inhibits dabigatran.&nbsp; Although dabigatran is a DOAC, it targets thrombin rather than factor Xa.</p><p><strong>(Choice D)</strong>&nbsp; Ticagrelor blocks the P2Y<font size=\"2\"><sub>12</sub></font> adenosine diphosphate receptor on the surface of platelets, which prevents platelet aggregation.&nbsp; Its activity is not mediated by factor Xa.</p><p><strong>(Choice E)</strong>&nbsp; Warfarin is a vitamin-K antagonist that prevents the generation of vitamin&ndash;K dependent clotting factors by blocking epoxide reductase in the liver.&nbsp; It is reversed by the administration of vitamin K.</p><p><strong>Educational objective:</strong><br>Andexanet alfa is a factor Xa decoy that has no proteolytic effect.&nbsp; It is administered to patients on factor Xa inhibitors (eg, rivaroxaban, apixaban) who have life-threatening bleeding in order to reverse the anticoagulation effect.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "13989",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 72-year-old man is brought to the hospital by paramedics after he was found disoriented and wandering in the street.&nbsp; He has a history of dementia, hypertension, and stroke.&nbsp; Physical examination reveals a disoriented, thin-appearing man.&nbsp; The gingivae are swollen and bleed easily.&nbsp; Ecchymoses are noted on the legs.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Hemoglobin</td><td>9.6 g/dL</td></tr><tr><td>Platelets</td><td>152,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>White blood cell count</td><td>4,500/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\"></td></tr><tr><td>Blood urea nitrogen</td><td>28 mg/dL</td></tr><tr><td>Serum creatinine</td><td>0.8 mg/dL</td></tr><tr><td colspan=\"2\"></td></tr><tr><td>PT</td><td>11 sec</td></tr><tr><td>PTT</td><td>30 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following is most likely responsible for this patient&#39;s ecchymoses?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Endothelial cell dysfunction"
        },
        {
          "id": 2,
          "text": "Fat-soluble vitamin deficiency"
        },
        {
          "id": 3,
          "text": "Hepatic dysfunction"
        },
        {
          "id": 4,
          "text": "Platelet dysfunction"
        },
        {
          "id": 5,
          "text": "Water-soluble vitamin deficiency"
        },
        {
          "id": 6,
          "text": "Zinc deficiency"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Vitamin C deficiency</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_T85566\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Vitamin C deficiency (scurvy)</strong></p></td></tr><tr><td><p align=\"center\"><strong>Pathogenesis</strong></p></td><td><ul><li>Malnutrition (eg, alcohol use disorder, anorexia, restricted diet)</li><li>Impaired collagen production &amp; connective tissue strength</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical manifestations</strong></p></td><td><ul><li>Cutaneous:<ul><li>Perifollicular hemorrhage, coiled hair</li><li>Petechiae, ecchymoses</li><li>Impaired wound healing</li></ul></li><li>Mucosal: gingivitis with bleeding</li><li>Musculoskeletal (eg, periosteal hemorrhage): arthralgias, weakness</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>Anemia (normocytic or microcytic)</li><li>Normal platelet count &amp; coagulation studies</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Vitamin C</li></ul></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient who is thin and disoriented has ecchymoses and gingival bleeding with normal platelets and coagulation factors.&nbsp; These findings are suggestive of <strong>vitamin C</strong> (ascorbic acid) <strong>deficiency (scurvy)</strong>, which typically occurs due to insufficient intake (eg, chronic alcohol use, malnourishment, restrictive diets).&nbsp; This patient&#39;s disorientation and thin body habitus are concerning for possible malnutrition and/or chronic substance use.</p><p>Vitamin C is a <strong>water-soluble</strong> vitamin that functions as a cofactor in collagen synthesis.&nbsp; <strong>Impaired collagen synthesis</strong> results in cutaneous signs of scurvy, including phrynoderma (perifollicular hyperkeratosis), coiled hair, and poor wound healing.&nbsp; <strong>Fragility of vasculature</strong> due to poor connective tissue strength can lead to hemorrhagic complications involving the mucosa (eg, <strong>gingival bleeding</strong>), skin (eg, <strong>ecchymoses, petechiae</strong>), and musculoskeletal system (eg, subperiosteal/intramuscular hemarthrosis causing limp/arthralgias).</p><p>Patients with scurvy frequently have anemia, which may be normocytic due to blood loss within tissues or microcytic due to associated poor iron intake or absorption.&nbsp; However, <strong>coagulation studies</strong> (PT, PTT) are <strong>normal</strong>&nbsp;(although exposed endothelial collagen normally activates the intrinsic clotting cascade, the in vitro PTT test uses alternate activating substances [eg, kaolin]&nbsp;and is not affected by defective collagen).</p><p><strong>(Choice A)</strong>&nbsp; Endothelial cell dysfunction in von Willebrand disease can lead to bleeding symptoms but would cause a prolonged PTT.&nbsp; In addition, this patient&#39;s thin habitus, disorientation, and anemia make vitamin C deficiency more likely than an inherited bleeding disorder.</p><p><strong>(Choice B)</strong>&nbsp; Deficiency in vitamin K, a fat-soluble vitamin, can lead to easy bruising and mucosal bleeding, but PT would be prolonged.</p><p><strong>(Choice C)</strong>&nbsp; Defective clotting factor production in liver disease can lead to easy bleeding, but prolongation of PT (and sometimes PTT) is expected.</p><p><strong>(Choice D)</strong>&nbsp; Platelet dysfunction in chronic kidney disease can cause easy bruising and mucosal bleeding with a normal platelet count and coagulation studies.&nbsp; However, this patient&#39;s normal creatinine level is inconsistent with declining kidney function, and azotemia alone (eg, due to dehydration) is not associated with platelet dysfunction.</p><p><strong>(Choice F)</strong>&nbsp; Zinc deficiency can present with an erosive dermatitis involving the perioral region, but gingival bleeding or easy bruising would be unexpected.</p><p><strong>Educational objective:</strong><br>Deficiency of vitamin C, a water-soluble vitamin, results in impaired collagen production.&nbsp; Manifestations include cutaneous findings of coiled hair and perifollicular keratosis, in addition to hemorrhagic complications such as gingival bleeding and easy bruising.&nbsp; PT, PTT, and platelet count are normal.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "7589",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 64-year-old woman is hospitalized for elective hip replacement surgery.&nbsp; She has osteoarthritis and is experiencing progressive right hip pain that limits her daily activities.&nbsp; The patient also has a history of hypertension and hypothyroidism.&nbsp; Her blood pressure is 130/80 mm Hg and pulse is 90/min.&nbsp; BMI is 31.5 kg/m<font size=\"2\"><sup>2</sup></font>.&nbsp; Her serum creatinine is 0.9 mg/dL.&nbsp; She undergoes surgery without complications and is postoperatively started on a medication that is a low molecular weight fraction of a negatively charged chemical stored in mast cell granules.&nbsp; Which of the following is the most likely mechanism of action of the medication used?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Binds antithrombin III"
        },
        {
          "id": 2,
          "text": "Binds to the thrombin active site"
        },
        {
          "id": 3,
          "text": "Blocks ADP receptors"
        },
        {
          "id": 4,
          "text": "Combines with proactivator plasminogen"
        },
        {
          "id": 5,
          "text": "Inhibits arachidonate product formation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"1600\"  src=\"https://www.uworld.com/media/L4869.jpg\" draggable=\"false\" ></p><p>Nonambulatory hospitalized patients are at increased risk for developing lower extremity <strong>deep venous thrombosis</strong> (DVT), which can lead to pulmonary embolism.&nbsp; In patients undergoing elective surgery without <strong>prophylaxis</strong> against DVT, the risk can be even higher, particularly with certain orthopedic procedures such as hip and knee replacement.&nbsp; In such cases, DVT prophylaxis is usually initiated within hours of wound closure.</p><p>Unfractionated and low molecular weight <strong>heparins</strong> (LMWHs) are commonly used for DVT prevention in inpatient settings.&nbsp; Administration of heparin (a negatively charged chemical naturally present in mast cells) increases the effect of the naturally occurring anticoagulant <strong>antithrombin III (AT III)</strong>.&nbsp; Unfractionated heparin binds to AT III via a pentasaccharide in the heparin chain.&nbsp; This results in a conformational change of AT III, which subsequently inhibits factor Xa and neutralizes thrombin, promoting anticoagulation.&nbsp; AT III activated by <strong>LMWH</strong> (which has better bioavailability and does not need laboratory monitoring when given therapeutically) acts predominantly on <strong>factor Xa</strong>, not thrombin.</p><p><strong>(Choice B)</strong>&nbsp; Direct thrombin inhibitors directly inhibit thrombin-mediated fibrin formation.&nbsp; Lepirudin and argatroban (parenteral) are primarily used for management of heparin-induced thrombocytopenia.&nbsp; Dabigatran (oral) is used for DVT prevention and treatment and for stroke prevention in atrial fibrillation.</p><p><strong>(Choice C)</strong>&nbsp; Clopidogrel and ticlopidine inhibit ADP-mediated platelet aggregation.&nbsp; They are useful following percutaneous coronary intervention and for treatment of unstable angina and non-ST segment elevation myocardial infarction.</p><p><strong>(Choice D)</strong>&nbsp; Use of drugs that convert inactive plasminogen to plasmin leads to fibrinolysis and clot lysis; such medications are given for clot lysis in acute myocardial infarction, pulmonary embolism, and arterial thrombosis.</p><p><strong>(Choice E)</strong>&nbsp; Aspirin irreversibly acetylates platelet cyclooxygenase-I, leading to decreased formation of thromboxane A2.&nbsp; Aspirin is used for primary and secondary prevention of myocardial infarction and stroke.</p><p><strong>Educational objective:</strong><br>Heparin is commonly used for the prevention of deep venous thrombosis in nonambulatory patients or those undergoing elective surgery, especially hip and knee surgery.&nbsp; Heparin increases the effect of the naturally occurring anticoagulant antithrombin III.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1077",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 63-year-old man comes to the hospital due to sudden onset chest pain and dyspnea.&nbsp; He has a history of glioblastoma multiforme, for which he has been undergoing radiation treatment.&nbsp; His temperature is 36.1 C (97 F), blood pressure is 110/80 mm Hg, pulse is 118/min, and respirations are 26/min.&nbsp; Pulse oximetry shows 90% on room air.&nbsp; A CT pulmonary angiogram demonstrates a left-sided pulmonary embolism.&nbsp; The patient is started on continuous unfractionated heparin infusion.&nbsp; Several hours later, the patient begins to experience severe headache and quickly becomes unconscious.&nbsp; A CT of the head reveals bleeding into the tumor.&nbsp; After stopping the heparin infusion, administration of which of the following is indicated for immediate anticoagulant reversal?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Fresh frozen plasma"
        },
        {
          "id": 2,
          "text": "Platelets"
        },
        {
          "id": 3,
          "text": "Protamine"
        },
        {
          "id": 4,
          "text": "Prothrombin complex concentrate"
        },
        {
          "id": 5,
          "text": "Tranexamic acid"
        },
        {
          "id": 6,
          "text": "Vitamin K"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t63248\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td></td><td><p align=\"center\"><strong>Warfarin overdose</strong></p></td><td><p align=\"center\"><strong>Heparin overdose</strong></p></td></tr><tr><td><p align=\"center\"><strong>Vitamin K</strong></p></td><td><ul><li>Effective (takes days)</li></ul></td><td><ul><li>Ineffective</li></ul></td></tr><tr><td><p align=\"center\"><strong>FFP</strong></p></td><td><ul><li>Effective (contains all blood clotting factors &amp; proteins)</li></ul></td><td><ul><li>Ineffective (contains antithrombin III &#8594; enhances heparin effect)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Protamine</strong></p></td><td><ul><li>Ineffective</li></ul></td><td><ul><li>Effective (heparin-specific antidote)</li></ul></td></tr><tr><td colspan=\"3\"><p><strong>FFP</strong> = fresh frozen plasma.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>Unfractionated heparin (UFH) and low-molecular weight heparins (LMWHs) are commonly used anticoagulants in the hospital setting.&nbsp; <a href=\"1600\">Heparin</a> increases the effect of the naturally occurring anticoagulant antithrombin III (ATIII).&nbsp; Activated partial thromboplastin time (aPTT) is measured to monitor the therapeutic effect of heparin.&nbsp; Bleeding and heparin-induced thrombocytopenia are serious complications of heparin therapy.&nbsp; <strong>Bleeding</strong> due to heparin toxicity is treated with <strong>protamine</strong> sulfate, a specific antagonist.&nbsp; Protamine sulfate is a peptide that binds to heparin, forming a complex that has no anticoagulant activity.&nbsp; Although protamine is often used in the management of LMWH toxicity, it does not completely reverse the anti-Xa activity of LMWH.</p><p><strong>Vitamin K</strong> is used for reversal of <strong>warfarin</strong> overdose but requires new synthesis of coagulation factors.&nbsp; As a result, its full effect takes time to manifest.&nbsp; For this reason, in the setting of acute life-threatening bleeding due to warfarin, fresh frozen plasma (<strong>FFP</strong>) (contains all blood proteins and clotting factors) should be given.&nbsp; However, FFP is <strong>not</strong> useful for heparin overdose as it contains ATIII, which can further potentiate the effects of heparin.&nbsp; <strong>Prothrombin complex concentrates</strong> (PCCs), which contain the vitamin K-dependent factors II, VII, IX, and X, can be used to treat bleeding due to warfarin (not heparin) overdose <strong>(Choices A, D, and F)</strong>.</p><p><strong>(Choices B and E)</strong>&nbsp; Platelet function is not significantly affected by heparin therapy; although heparin-induced thrombocytopenia can occur in a minority of patients, this complication usually develops after several days (not hours).&nbsp; Aminocaproic acid and tranexamic acid inhibit fibrinolysis by inhibiting plasminogen activation.</p><p><strong>Educational objective:</strong><br>Protamine sulfate binds to heparin, causing chemical inactivation.&nbsp; Vitamin K and fresh frozen plasma can be used to reverse warfarin effects.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1087",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 52-year-old man comes to the emergency department (ED) due to 2 hours of burning substernal pain.&nbsp; Before coming to the ED, he took several tablets of antacid at home without any relief.&nbsp; The patient&#39;s other medical problems include hypertension and hyperlipidemia.&nbsp; His temperature is 36.7 C (98 F), blood pressure is 160/90 mm Hg, and pulse is 92/min.&nbsp; Cardiovascular examination shows normal S1 and S2 without any murmurs.&nbsp; There is no abdominal tenderness.&nbsp; ECG shows ST-segment depression in leads II, III, and aVF.&nbsp; Troponin is 0.06 ng/mL (normal &lt;0.01 ng/mL).&nbsp; As part of this patient&#39;s treatment, enoxaparin therapy is initiated.&nbsp; This drug is expected to bind to which of the following substances in this patient&#39;s blood?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Antithrombin III"
        },
        {
          "id": 2,
          "text": "Fibrin"
        },
        {
          "id": 3,
          "text": "Plasminogen"
        },
        {
          "id": 4,
          "text": "Protein C"
        },
        {
          "id": 5,
          "text": "Prothrombin"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img id=\"1600\"  src=\"https://www.uworld.com/media/L4869.jpg\" draggable=\"false\" ></p><p>This patient with chest pain, ST depressions, and mild troponin elevation appears to be experiencing a myocardial infarction.&nbsp; <strong>Enoxaparin</strong> is a form of low-molecular-weight heparin (LMWH) that, like heparin, functions by binding <strong>antithrombin III</strong> (AT III) via a pentasaccharide sequence.&nbsp; Once activated, AT III binds to <strong>factor Xa</strong> and stops factor Xa from converting prothrombin to thrombin.&nbsp; Less thrombin is produced, resulting in an anticoagulant effect.</p><p>Unfractionated heparin has more molecules than LMWH, allowing it to bind factor Xa and thrombin; it is more effective than LMWH in inactivating thrombin.</p><p><strong>(Choices B and C)</strong>&nbsp; Tissue plasminogen activator (t-PA) converts plasminogen to plasmin.&nbsp; Plasmin functions to break down fibrin, resulting in thrombolysis.&nbsp; Because t-PA can only bind plasminogen strongly in the presence of fibrin, its thrombolytic action is clot specific.</p><p><strong>(Choice D)</strong>&nbsp; Protein C and protein S are endogenous antithrombotic molecules that are also vitamin K-dependent.&nbsp; Due to their shorter half-lives in the circulation, these molecules are depleted first during initiation of warfarin therapy, causing a transient procoagulant state.&nbsp; For this reason, patients are typically treated with heparin or LMWH during initiation of warfarin therapy.</p><p><strong>(Choice E)</strong>&nbsp; Prothrombin (factor II) is a vitamin K-dependent clotting factor.&nbsp; This factor, along with factors VII, IX, and X, is depleted by warfarin.&nbsp; LMWHs inhibit prothrombin production (through factor X inhibition), but they do not directly bind prothrombin.</p><p><strong>Educational objective:</strong><br>Enoxaparin is a low-molecular-weight heparin (LMWH) that functions like heparin in that it binds and activates antithrombin III (AT III).&nbsp; Activated AT III binds to factor Xa and stops factor Xa from converting prothrombin to thrombin.&nbsp; Due to its fewer number of molecules, LMWH acts primarily on factor Xa, not thrombin.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1784",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 24-year-old woman, gravida 1 para 0, at 28 weeks gestation comes to the labor and delivery unit due to intense abdominal pain, vaginal bleeding, and absent fetal movement.&nbsp; Temperature is 36.7 C (98.1 F), blood pressure is 170/96 mm Hg, pulse is 108/min, and respirations are 22/min.&nbsp; Pulse oximetry shows 98% on room air.&nbsp; Physical examination shows a tense abdomen and a firm, tender uterus.&nbsp; Ultrasound shows a hematoma between the placenta and the uterine wall and no fetal cardiac activity.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Hemoglobin</td><td>9.2 g/dL</td></tr><tr><td>Platelets</td><td>60,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>Aspartate aminotransferase (SGOT)</td><td>12 U/L</td></tr><tr><td>Alanine aminotransferase (SGPT)</td><td>24 U/L</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>The patient is hospitalized for further management.&nbsp; Once hospitalized, she begins to experience bleeding from her gums and intravenous catheter sites.&nbsp; Blood is also noted in the urinary catheter.&nbsp; Vital signs are unchanged, and she reports no shortness of breath.&nbsp; Which of the following is the most likely underlying cause of this patient&#39;s hospital symptoms?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Embolization of amniotic fluid into the maternal circulation"
        },
        {
          "id": 2,
          "text": "Ascending polymicrobial infection of the endometrial lining"
        },
        {
          "id": 3,
          "text": "Decidual tissue factor release into the maternal circulation"
        },
        {
          "id": 4,
          "text": "Hepatic fatty infiltration with decreased clotting factor production"
        },
        {
          "id": 5,
          "text": "Complete rupture of the endometrium, myometrium, and serosa"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > DIC</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"3902\" src=\"https://www.uworld.com/media/L27482.png\" ></p><p>This pregnant patient with new bleeding from the gums and catheter sites likely has <strong>disseminated intravascular coagulation (DIC)</strong>, a life-threatening complication that can occur with postpartum hemorrhage, <a href=\"2483\">abruptio placentae</a>, or amniotic fluid embolism.&nbsp; This patient has DIC due to&nbsp;<strong>abruptio placentae</strong> (ie, placental bleeding between the uterine wall and placenta), which results in premature placental separation, fetal hypoxia, and in severe cases, <strong>fetal demise</strong>.&nbsp; Patients with abruptio placentae typically have vaginal bleeding, uterine rigidity and/or tenderness, and contractions.&nbsp; Maternal hypertension (eg, preeclampsia) and tobacco use are risk factors.</p><p>Severe placental abruption (eg, retroplacental hematoma) causes <strong>decidual damage and ischemia</strong>, thereby triggering&nbsp;<strong>tissue factor release</strong> into the maternal circulation.&nbsp; Tissue factor, a procoagulant, then activates the extrinsic pathway of the <a href=\"4730\">coagulation cascade</a> to cause excessive thrombin generation with formation of circulating platelet-fibrin microthrombi.&nbsp; As clotting factors and platelets are rapidly consumed, a consumptive coagulopathy (eg,&nbsp;<strong>thrombocytopenia</strong>, prolonged PT &amp; aPTT) develops that&nbsp;results in&nbsp;profound bleeding, classically from mucosal surfaces and intravenous line sites.</p><p><strong>(Choice A)</strong>&nbsp; Amniotic fluid embolism (AFE) introduces fetal antigens and tissue factor from the amniotic fluid into the maternal circulation, triggering a massive immune response and increased release of procoagulant factors that can lead to DIC.&nbsp; However, AFE typically causes maternal circulatory collapse with severe hypotension, making this diagnosis less likely in this patient.</p><p><strong>(Choice B)</strong>&nbsp; An ascending polymicrobial infection of the endometrial lining (eg, postpartum endometritis) can cause uterine tenderness, vaginal bleeding, and sepsis, thereby precipitating DIC.&nbsp; However, patients typically also have fever and hypotension.</p><p><strong>(Choice D)</strong>&nbsp; Acute fatty liver of pregnancy, characterized by microvesicular fatty infiltration of hepatocytes, can impair maternal hepatic function, reducing production of clotting factors and impairing clearance of fibrin degradation products, which may result in DIC.&nbsp; However, patients typically have elevated liver transaminases.</p><p><strong>(Choice E)</strong>&nbsp; Complete <a href=\"1057\">uterine rupture</a> through the endometrium, myometrium, and serosa can cause vaginal bleeding, abdominal pain, and fetal compromise.&nbsp; However, patients usually have had a prior uterine surgery and present with palpable fetal parts protruding through the disrupted uterine wall rather than a firm, tense uterus.</p><p><strong>Educational objective:</strong><br>Disseminated intravascular coagulation (DIC) can occur with abruptio placentae due to release of tissue factor, a procoagulant that activates the coagulation cascade, from the damaged decidua into the maternal circulation.&nbsp; DIC classically presents with thrombocytopenia and bleeding from mucosal surfaces (eg, gums) and intravenous line sites.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1296",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 63-year-old man comes to the emergency department because of 1 hour of sudden-onset chest pain.&nbsp; He developed the pain after eating dinner and did not have relief with antacids.&nbsp; His other medical problems include hypertension, hyperlipidemia, and type 2 diabetes mellitus.&nbsp; In the emergency department, his blood pressure is 100/60 mm Hg, pulse is 100/min, and respirations are 18/min.&nbsp; His EKG shows ST-segment depression in the inferior leads, and his cardiac serum troponin T is positive.&nbsp; The following anticoagulants are being considered for treatment:</p><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td align=\"center\"><strong>Anticoagulant</strong></td><td align=\"center\"><strong>Molecular Weight</strong></td></tr><tr><td>Unfractionated heparin</td><td>5000-30,000 u</td></tr><tr><td>Enoxaparin</td><td>3000-8000 u</td></tr><tr><td>Fondaparinux</td><td>Pentasaccharide</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following anticoagulants is most effective in inactivating thrombin?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Enoxaparin"
        },
        {
          "id": 2,
          "text": "Fondaparinux"
        },
        {
          "id": 3,
          "text": "Unfractionated heparin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This patient presents with findings consistent with acute coronary syndrome, with ongoing injury as evidenced by the positive troponin.&nbsp; An important component of therapy involves not only treating the existing clot but also preventing its propagation.&nbsp; The coagulation cascade amplifies the generation of thrombin, which activates platelets to form a plug and also helps convert fibrinogen to fibrin to reinforce the platelet plug.&nbsp; Antithrombin can inhibit both Factor Xa in the coagulation cascade and also thrombin.</p><p><img draggable=\"false\" id=\"1600\" src=\"https://www.uworld.com/media/L4869.jpg\" ></p><p>Both unfractionated heparin and low molecular weight heparin (LMWH) contain a pentasaccharide sequence that binds to antithrombin and causes a conformational change that increases its ability to inactivate Factor Xa.&nbsp; However, heparin must bind to both antithrombin and thrombin together to form a ternary complex to inactivate thrombin.&nbsp; Only unfractionated heparin (not LMWH) has a pentasaccharide chain long enough (&gt;18 saccharide units) to bind to both antithrombin and thrombin.&nbsp; As a result, unfractionated heparin has equal activity against Factor Xa and thrombin, while LMWH has greater activity against Factor Xa than thrombin.</p><p><strong>(Choice A)</strong>&nbsp; Enoxaparin is a low molecular weight heparin that has fewer of the required long saccharide units that bind to thrombin and less antithrombotic activity compared to unfractionated heparin.</p><p><strong>(Choice B)</strong>&nbsp; Fondaparinux is a synthetic pentasaccharide Factor Xa inhibitor.&nbsp; It has none of the required long saccharide units that bind to thrombin and much lower antithrombin activity compared to unfractionated heparin.</p><p><strong>Educational objective:</strong><br>Both unfractionated heparin and LMWH can bind to antithrombin to increase its activity against Factor Xa.&nbsp; Only unfractionated heparin is able to bind to both antithrombin and thrombin to allow antithrombin to inactivate thrombin.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "2132",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 32-year-old woman experiences 3 episodes of deep venous thrombosis in a 6-year period.&nbsp; She has a history of pulmonary embolism as well.&nbsp; The patient&#39;s partial thromboplastin time (PTT) is within normal limits, and remains unchanged when activated protein C is added to her plasma.&nbsp; The most likely cause of this patient&#39;s problem is:</p>",
      "choices": [
        {
          "id": 1,
          "text": "Immune"
        },
        {
          "id": 2,
          "text": "Nutritional"
        },
        {
          "id": 3,
          "text": "Inherited"
        },
        {
          "id": 4,
          "text": "Infectious"
        },
        {
          "id": 5,
          "text": "Neoplastic"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Inherited thrombophilia</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This is a young patient with recurrent deep venous thromboses, features indicative of a hypercoagulable state.&nbsp; Inherited causes of hypercoagulability must be considered in all patients under age 50 who present with thromboses in the absence of any obvious explanation for an acquired prothrombotic state.</p><p>The patient&#39;s plasma is resistant to the normally antithrombotic effects of activated protein C.&nbsp; Thus, the most likely diagnosis is a mutation in the factor V gene, which renders factor Va resistant to inactivation by activated protein C.&nbsp; A specific factor V mutation, known as the Leiden mutation, and mutations in the prothrombin gene are the most common inherited causes of hypercoagulability.&nbsp; Activated protein C resistance (factor V Leiden mutation) is detected in approximately 20% (range 12&ndash;40%) of patients with abnormal venous thromboses.</p><p><b>(Choice A) </b>Antiphospholipid antibody syndrome is a common immune cause of hypercoagulability. &nbsp;This condition is defined by the presence of antiphospholipid antibodies (lupus anticoagulant and/or anticardiolipin antibodies) plus one or more of the following: venous thromboembolism, arterial thromboembolism, or frequent fetal loss.&nbsp; Unlike the patient in the vignette, patients with antiphospholipid antibody syndrome typically have a prolonged baseline aPTT.&nbsp; Lupus anticoagulants are the most common cause of aPTT prolongation.</p><p><b>(Choice B) </b>Folic acid deficiency can cause hyperhomocysteinemia, which is a prothrombotic state.&nbsp; However, activated protein C resistance is not seen with this condition.</p><p><b>(Choice D) </b>Endovascular infections and/or systemic inflammatory states may affect vascular endothelial cells in a way that favors thrombosis.&nbsp; However, infection and inflammatory mediators do not directly promote activated protein C resistance in the aPTT coagulation test.</p><p><b>(Choice E) </b>A paraneoplastic syndrome of hypercoagulability may be seen in some patients with cancer, especially patients with adenocarcinomas of the pancreas, colon, or lung.&nbsp; The mechanism of cancer-induced hypercoagulability is thought to involve release of procoagulant tumor products.&nbsp; Vascular stasis due to obstruction of blood flow by the tumor, patient immobility, hepatic involvement and dysfunction, sepsis, and advanced age may also contribute to the tendency toward thrombosis in cancer patients.&nbsp; None of these mechanisms/factors directly promotes activated protein C resistance in the aPTT coagulation test.</p><p><b>Educational Objective:</b><br>Inherited causes of hypercoagulability should be considered in patients younger than age 50 who present with thrombosis and no obvious explanation for an acquired prothrombotic state.&nbsp; The factor V Leiden mutation, which causes factor Va resistance to inactivation by activated protein C, may account for approximately 20% of cases of atypical venous thrombosis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "465",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 26-year-old woman is being evaluated for glomerulonephritis, a photosensitive skin rash, and arthralgia.&nbsp; Rapid plasma reagin (RPR) test is repeatedly positive despite negative <em>Treponema pallidum</em> enzyme immunoassay (TP-EIA) testing.&nbsp; Coagulation study results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Bleeding time</td><td>normal</td></tr><tr><td>Activated PTT</td><td>prolonged</td></tr><tr><td>PT</td><td>normal</td></tr><tr><td>Platelets</td><td>240,000/mm<font size=\"2\"><sup>3</sup></font></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>This patient is at greatest risk for which of the following complications?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Heavy menstrual bleeding"
        },
        {
          "id": 2,
          "text": "Painful hemarthroses"
        },
        {
          "id": 3,
          "text": "Recurrent miscarriages"
        },
        {
          "id": 4,
          "text": "Sclerodactyly"
        },
        {
          "id": 5,
          "text": "Tabes dorsalis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Antiphospholipid syndrome</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t80877\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Antiphospholipid antibody syndrome</strong></p></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><p><strong>Venous or arterial thromboembolic disease</strong></p><ul><li>Deep vein thrombosis</li><li>Pulmonary embolism</li><li>Ischemic stroke/transient ischemic attack</li></ul>&nbsp;<p><strong>Adverse pregnancy outcomes</strong></p><ul><li>Unexplained embryonic or fetal loss</li><li>Premature birth due to placental insufficiency or preeclampsia</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>Lupus anticoagulant effect: paradoxical activated PTT prolongation not reversed on plasma mixing studies</li><li>Presence of specific antiphospholipid antibodies<ul><li>Anticardiolipin antibody</li><li>Anti&ndash;&beta;2-glycoprotein I antibody</li></ul></li></ul></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient with glomerulonephritis, photosensitive skin rash, and arthralgia has <a href=\"4254\">systemic lupus erythematosus</a> (SLE).&nbsp; Many patients with SLE have circulating <strong>antiphospholipid antibodies</strong> (ie, lupus anticoagulant [LA], anticardiolipin antibody [aCL], anti-beta-2 glycoprotein I antibody).</p><p>Antiphospholipid antibodies interfere with common serologic tests: LA cross-reacts with phospholipid reagents in the activated PTT test, and aCL binds cardiolipin, the predominant antigen used in the rapid plasma reagin (RPR) and VDRL tests.&nbsp; Therefore, patients with circulating antiphospholipid antibodies have <strong>paradoxical PTT prolongation</strong> and <strong>false-positive RPR/VDRL results</strong>.&nbsp; Bleeding time and PT, which are coagulation tests unaffected by antiphospholipid antibodies, are normal.</p><p>Patients with antiphospholipid antibodies (with or without the concomitant diagnosis of SLE) are at risk for antiphospholipid antibody syndrome (APS), a <strong>hypercoagulable disorder</strong> characterized by venous (eg, deep vein thrombosis) or arterial (eg, ischemic stroke) thrombosis.&nbsp; The presence of antiphospholipid antibodies promotes <strong>thromboembolism</strong> due to activation of phospholipid-dependent coagulation pathways.</p><p>Patients with APS have increased obstetric morbidity, including <strong>recurrent pregnancy loss</strong>, preterm delivery due to preeclampsia or placental insufficiency, and stillbirth.&nbsp; The underlying mechanism is likely <strong>thrombosis of placental vessels</strong>, which decreases perfusion to the fetus.</p><p><strong>(Choices A and B)</strong>&nbsp; Hemophilias (eg, inherited deficiency of factor VIII, IX, or XI) can cause prolonged activated PTT but normal PT; these patients may have heavy menstrual bleeding and/or painful hemarthroses (bleeding into a joint).&nbsp; However, in the setting of SLE, this patient&#39;s abnormal coagulation test results are more consistent with interference by antiphospholipid antibodies than an inherited coagulopathy.</p><p><strong>(Choice D)</strong>&nbsp; <a href=\"50467\">Sclerodactyly</a> can occur with other autoimmune diseases such as scleroderma or CREST (<strong>C</strong>alcinosis cutis, <strong>R</strong>aynaud phenomenon, <strong>E</strong>sophageal dysmotility, <strong>S</strong>clerodactyly, <strong>T</strong>elangiectasia) syndrome.&nbsp; However, it is does not typically occur with SLE.</p><p><strong>(Choice E)</strong>&nbsp; Tabes dorsalis is a manifestation of tertiary syphilis that results in sensory ataxia.&nbsp; Because this patient has a negative specific treponemal test (<em>Treponema pallidum</em> enzyme immunoassay [TP-EIA]), her positive RPR test result is likely a false-positive, and therefore she is not at risk for tabes dorsalis.</p><p><strong>Educational objective:</strong><br>Many patients with systemic lupus erythematosus have antiphospholipid antibodies, which can cause paradoxical PTT prolongation and false-positive RPR/VDRL results; antiphospholipid antibody syndrome is characterized by arterial or venous thrombosis and increased obstetric morbidity (eg, recurrent pregnancy loss).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "742",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 72-year-old man comes to the emergency department due to severe chest tightness and dyspnea that started 20 minutes ago at a family dinner.&nbsp; He has never experienced similar symptoms before.&nbsp; The patient&#39;s medical conditions include hypertension, hyperlipidemia, type 2 diabetes mellitus, and prostate cancer.&nbsp; He takes multiple medications and has no drug allergies.&nbsp; The patient smoked a pack of cigarettes daily for 30 years but stopped smoking 10 years ago.&nbsp; Chest CT scan with contrast is shown in the image below.</p><p><img  draggable=\"false\" id=\"2947\" src=\"https://www.uworld.com/media/highresdefault/U69.png\"  ></p><p>Which of the following factors most likely contributed to this patient&#39;s current condition?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Atherosclerosis"
        },
        {
          "id": 2,
          "text": "Fluid overload"
        },
        {
          "id": 3,
          "text": "Hypercoagulability"
        },
        {
          "id": 4,
          "text": "Intimal tear"
        },
        {
          "id": 5,
          "text": "Noninfectious vasculitis"
        },
        {
          "id": 6,
          "text": "Pulmonary bleb rupture"
        },
        {
          "id": 7,
          "text": "Pulmonary metastasis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Pulmonary embolism</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img  draggable=\"false\" id=\"663\" src=\"https://www.uworld.com/media/highresdefault/L69.png\"  ></p><p>This patient is experiencing sudden-onset chest tightness and dyspnea, and CT scan of the chest shows a <strong>saddle pulmonary embolism</strong> (PE) straddling the bifurcation of the main pulmonary artery.&nbsp; The main pulmonary artery, usually comparable in diameter to the ascending aorta, is significantly dilated due to the proximal increase in hydrostatic pressure from the PE.&nbsp; Saddle PE can result in sudden cardiac death or severe hypotension, but many patients can be hemodynamically stable on presentation.</p><p>Venous thromboembolism (VTE) (ie, PE or deep venous thrombosis) results from the <a href=\"2121\">Virchow triad</a> of endothelial injury, venous stasis, and a <strong>hypercoagulable</strong> state.&nbsp; <strong>Malignancy</strong> (eg, prostate cancer) induces a hypercoagulable state and is a strong risk factor for VTE.&nbsp; Active <strong>smoking</strong> is also a risk factor as it contributes to endothelial injury and a hypercoagulable state.&nbsp; Age plays a role as well, as older individuals tend to be more <strong>sedentary</strong> and are more prone to venous stasis.</p><p><strong>(Choice A)</strong>&nbsp; Atherosclerosis primarily affects the higher pressure arteries in the systemic circulation (eg, aorta, popliteal arteries, carotid arteries) and the coronary arteries.&nbsp; Significant atherosclerosis in the relatively low-pressure pulmonary arteries is rare.</p><p><strong>(Choice B)</strong>&nbsp; Fluid overload causes <a href=\"53473\">pulmonary edema</a>, typically appearing as alveolar ground glass opacities on CT scan.&nbsp; This patient&#39;s lungs appear clear of airspace disease.</p><p><strong>(Choice D)</strong>&nbsp; An intimal tear can lead to <a href=\"66\">aortic dissection</a>, which classically manifests as severe chest pain radiating to the back.&nbsp; Pulmonary artery dissection is extremely rare.</p><p><strong>(Choice E)</strong>&nbsp; Pulmonary vasculitis (eg, granulomatosis with polyangiitis) could cause dyspnea and chest tightness but would demonstrate an interstitial pattern on CT scan, sometimes leading to <a href=\"53474\">pulmonary hemorrhage</a>.</p><p><strong>(Choice F)</strong>&nbsp; Rupture of <a href=\"2949\">pulmonary blebs</a> (thin-walled, air-filled subpleural structures) leads to pneumothorax.</p><p><strong>(Choice G)</strong>&nbsp; For <a href=\"45236\">pulmonary metastasis</a> to cause significant dyspnea, multiple lesions would likely be present.&nbsp; There is no evidence of lung masses on this patient&#39;s CT scan.</p><p><strong>Educational objective:</strong><br>Saddle pulmonary embolism straddles the bifurcation of the main pulmonary artery.&nbsp; Venous thromboembolism (ie, pulmonary embolism or deep vein thrombosis) arises due to the Virchow triad of endothelial injury, venous stasis, and a hypercoagulable state.&nbsp; Malignancy causes a hypercoagulable state and is a strong risk factor for venous thromboembolism.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1880",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 50-year-old woman with a history of systemic lupus erythematosus is admitted with fever, chills, vomiting, and burning pain when urinating.&nbsp; Temperature is 39.3 C (102.7 F), blood pressure is 80/50 mm Hg, pulse is 120/min, and respirations are 20/min.&nbsp; On examination, costovertebral angle tenderness is present.&nbsp; The patient is given intravenous antibiotics.&nbsp; Over the next several hours, she has decreased urine output despite aggressive intravenous hydration.&nbsp; Blood is oozing around the central venous catheter.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td>9.0 g/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td>68,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td>24,500/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\">Coagulation studies</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Prothrombin time</td><td>23 sec</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Partial thromboplastin time</td><td>60 sec</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Plasma fibrinogen</td><td>100 mg/dL (150-350)</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following is the most likely cause of this patient&#39;s hematologic abnormalities?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Accumulation of anticardiolipin antibodies"
        },
        {
          "id": 2,
          "text": "Accumulation of ultra-large von Willebrand factor multimers"
        },
        {
          "id": 3,
          "text": "Consumptive coagulopathy"
        },
        {
          "id": 4,
          "text": "Immune-mediated platelet destruction"
        },
        {
          "id": 5,
          "text": "Impaired hepatic synthetic activity"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > DIC</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t50361\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"6\"><p align=\"center\"><strong>Laboratory characteristics of coagulopathies</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>Platelet count</strong></p></td><td><p align=\"center\"><strong>Prothrombin time</strong></p></td><td><p align=\"center\"><strong>Partial thromboplastin time</strong></p></td><td><p align=\"center\"><strong>Plasma fibrinogen values</strong></p></td><td><p align=\"center\"><strong>Peripheral blood smear</strong></p></td></tr><tr><td><p><strong>von Willebrand disease</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p><strong>Immune thrombocytopenic purpura</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Isolated thrombocytopenia</p></td></tr><tr><td><p><strong>TTP-HUS</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">RBC fragmentation</p></td></tr><tr><td><p><strong>Disseminated intravascular coagulation</strong></p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8593;</p></td><td><p align=\"center\">&#8595;</p></td><td><p align=\"center\">RBC fragmentation</p></td></tr><tr><td colspan=\"6\"><strong>HUS</strong> = hemolytic uremic syndrome; <strong>RBC</strong> = red blood cell; <strong>TTP</strong> = thrombotic thrombocytopenic purpura.</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient&#39;s costovertebral angle tenderness, dysuria, and leukocytosis are indicative of acute pyelonephritis complicated by septic shock (hypotension, tachycardia).&nbsp; Her laboratory results show a consumptive coagulopathy (thrombocytopenia, prolonged PT/PTT, low fibrinogen), which, along with bleeding from the central catheter site, are likely due to <strong>disseminated intravascular coagulation</strong> (DIC).</p><p>DIC is a common complication of <strong>sepsis </strong>(particularly with gram-negative organisms) because <strong>lipopolysaccharide </strong>is a <strong>procoagulant </strong>that triggers the coagulation cascade.&nbsp; This leads to the formation of fibrin- and platelet-rich thrombi in the vasculature, which consumes platelets <strong>(thrombocytopenia)</strong>, coagulation factors <strong>(prolonged PT/PTT)</strong>, and fibrinogen.&nbsp; Fibrinolysis is then triggered to degrade the clots, which <strong>elevates D-dimer</strong> (a fibrin degradation product) and depletes protein C, protein S, and antithrombin.&nbsp; The thrombi also often shear red blood cells, leading to <strong>microangiopathic hemolytic anemia</strong> (MAHA).</p><p>Most patients with acute DIC have signs of bleeding, such as <strong>oozing from vascular catheters</strong>, mucocutaneous bleeding, ecchymosis, or petechiae.&nbsp; End organ damage (eg, renal insufficiency, pulmonary hemorrhage) is also common.</p><p><strong>(Choice A)</strong>&nbsp; Anticardiolipin antibody is antiphospholipid antibody often seen in patients with lupus erythematosus.&nbsp; It can cause antiphospholipid antibody syndrome, which is marked by thromboembolism and fetal loss (not bleeding).&nbsp; Although patients often have prolonged PTT (because the antiphospholipid interferes with the PTT test), PT is normal.</p><p><strong>(Choice B)</strong>&nbsp; Thrombotic thrombocytopenic purpura (TTP) is caused by reduced activity of von Willebrand factor&ndash;cleaving protein ADAMTS13, leading to the accumulation of ultra-large von Willebrand factor multimers that trap platelets and generate platelet-rich thrombi in the microvasculature.&nbsp; Although patients usually develop thrombocytopenia, MAHA, fever, confusion, and organ damage (eg, acute renal failure), the coagulation cascade is unaffected; therefore, PT/PTT and fibrinolysis (fibrinogen level) are normal, and bleeding does not occur.</p><p><strong>(Choice D)</strong>&nbsp; Immune (idiopathic) thrombocytopenic purpura (ITP) is marked by autoantibodies to platelets/megakaryocytes; thrombocytopenia is the only peripheral blood abnormality.&nbsp; Coagulation studies (eg, PT, PTT) and fibrinogen levels are normal.&nbsp; Spontaneous bleeding is very uncommon unless the platelet count is &lt;10,000/mm<font size=\"2\"><sup>3</sup></font>.</p><p><strong>(Choice E)</strong>&nbsp; The liver generates thrombopoietin and the majority of clotting factors.&nbsp; Therefore, patients with significantly impaired hepatic function (eg, cirrhosis) sometimes have mild thrombocytopenia and prolonged coagulation studies.&nbsp; However, fibrinogen level is usually normal and this patient has no other signs of advanced hepatic dysfunction (eg, ascites, jaundice).</p><p><strong>Educational objective:</strong><br>Disseminated intravascular coagulation commonly occurs in the setting of sepsis and is characterized by widespread activation of the coagulation cascade with formation of microthrombi.&nbsp; Laboratory results reveal prolonged PT/PTT, thrombocytopenia, and low fibrinogen (ie, a consumptive coagulopathy), and patients usually have signs of bleeding (eg, oozing from venipuncture sites).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1298",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 40-year-old man with end-stage renal disease due to type 1 diabetes mellitus is hospitalized for initiation of hemodialysis.&nbsp; A tunneled dialysis catheter is inserted into the right internal jugular vein.&nbsp; Before he is able to undergo dialysis treatment, the patient develops bleeding around the catheter exit site that is difficult to control.&nbsp; He has not been treated recently with anticoagulants.&nbsp; Further evaluation of this patient would most likely show which of the following laboratory abnormalities?</p>",
      "choices": [
        {
          "id": 1,
          "text": "NormalNormalNormalProlonged"
        },
        {
          "id": 2,
          "text": "NormalProlongedNormalProlonged"
        },
        {
          "id": 3,
          "text": "NormalProlongedNormalNormal"
        },
        {
          "id": 4,
          "text": "ProlongedProlongedDecreasedProlonged"
        },
        {
          "id": 5,
          "text": "ProlongedProlongedNormalNormal"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > Coagulopathy</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><div id=\"div_t80873\"><table class=\"table-default-style table-header-footer-style\"><tbody><tr><td colspan=\"5\"><p align=\"center\"><strong>Laboratory characteristics of coagulopathies</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>PT</strong></p></td><td><p align=\"center\"><strong>aPTT</strong></p></td><td><p align=\"center\"><strong>Platelet count</strong></p></td><td><p align=\"center\"><strong>Bleeding time</strong></p></td></tr><tr><td><p align=\"center\"><strong>Hemophilia<br />A &amp; B</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&uarr;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p align=\"center\"><strong>Von Willebrand factor deficiency</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal or &uarr;</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&uarr;</p></td></tr><tr><td><p align=\"center\"><strong>Disseminated intravascular coagulation</strong></p></td><td><p align=\"center\">&uarr;</p></td><td><p align=\"center\">&uarr;</p></td><td><p align=\"center\">&darr;</p></td><td><p align=\"center\">&uarr;</p></td></tr><tr><td><p align=\"center\"><strong>Uremic platelet dysfunction</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&uarr;</p></td></tr><tr><td><p align=\"center\"><strong>Heparin administration</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&uarr;</p></td><td><p align=\"center\">Normal (except in heparin-induced thrombocytopenia)</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p align=\"center\"><strong>Warfarin use</strong></p></td><td><p align=\"center\">&uarr;</p></td><td><p align=\"center\">&uarr; (weak effect)</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td></tr><tr><td><p align=\"center\"><strong>Immune thrombocytopenia</strong></p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">Normal</p></td><td><p align=\"center\">&darr;</p></td><td><p align=\"center\">&uarr;</p></td></tr><tr><td colspan=\"5\"><p><strong>aPTT</strong> = <strong>activated partial thromboplastin time;</strong><strong>PT</strong> = prothrombin time.</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div></p><p>Excessive bleeding is common in patients with significant renal dysfunction due in part to the accumulation of <strong>uremic toxins</strong> in the circulation.&nbsp; These toxins impair platelet aggregation and adhesion, resulting in a <strong>qualitative platelet disorder</strong> characterized by <strong>prolonged bleeding time</strong> with normal platelet count, prothrombin time (PT), and activated partial thromboplastin time (aPTT).&nbsp; Uremic bleeding can be improved with <strong>dialysis</strong> as it removes the toxins and partially reverses the bleeding abnormality.</p><p><strong>(Choice B)</strong>&nbsp; von Willebrand factor (vWF) acts as a bridge between glycoprotein 1b receptors and subendothelial collagen, allowing platelets to bind to damaged vessels.&nbsp; vWF deficiency results in platelet dysfunction with a prolonged bleeding time and normal platelet count.&nbsp; Since vWF also protects factor VIII from degradation, vWF deficiency can result in decreased factor VIII and prolonged aPTT.</p><p><strong>(Choice C)</strong>&nbsp; Isolated aPTT prolongation is seen with hemophilia A, an X-linked disorder caused by factor VIII deficiency.&nbsp; Heparin use also prolongs the aPTT via antithrombin-associated inhibition of factors II and X (PT is usually normal due to the addition of heparin neutralizers in the PT reagent).</p><p><strong>(Choice D)</strong>&nbsp; Disseminated intravascular coagulation is a consumptive coagulopathy associated with decreased platelet count and increased bleeding time, aPTT, and PT.</p><p><strong>(Choice E)</strong>&nbsp; Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, and X).&nbsp; Warfarin prolongs both PT and aPTT, but PT is increased much more than aPTT.&nbsp; Platelet count and bleeding time are normal.</p><p><strong>Education objective:</strong><br>Abnormal bleeding in patients with uremia is due to a qualitative platelet disorder that causes prolonged bleeding time with normal platelet count, prothrombin time, and activated partial thromboplastin time.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1293",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 20-year-old man is brought to the emergency department due to fever, headache, and neck pain for the last day.&nbsp; He has no significant medical history.&nbsp; Temperature is 38.7 C (101.7 F), blood pressure is 120/72 mm Hg, pulse is 112/min, and respirations are 26/min.&nbsp; There is neck stiffness and a petechial rash on the trunk.&nbsp; Cerebrospinal fluid (CSF) analysis reveals the following:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Glucose</td><td>30 mg/dL</td></tr><tr><td>Protein</td><td>180 mg/dL</td></tr><tr><td>Leukocytes</td><td>1,500/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Neutrophils</td><td>70%</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>CSF gram stain shows gram-negative diplococci.&nbsp; In the emergency department, the patient&#39;s hemodynamic status deteriorates rapidly.&nbsp; Blood pressure drops to 80/50 mm Hg, and the venous access sites are oozing blood.&nbsp; Which of the following findings is most likely to be seen on this patient&#39;s peripheral blood smear?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Atypical lymphocytosis"
        },
        {
          "id": 2,
          "text": "Howell-Jolly bodies"
        },
        {
          "id": 3,
          "text": "Hypersegmented neutrophils"
        },
        {
          "id": 4,
          "text": "Reactive thrombocytosis"
        },
        {
          "id": 5,
          "text": "Schistocytes"
        },
        {
          "id": 6,
          "text": "Severe pancytopenia"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathology > Hematology & Oncology > DIC</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"24482\" src=\"https://www.uworld.com/media/L50403.jpg\" ></p><p>This patient&#39;s clinical findings (fever, headache, neck stiffness, rash) and cerebrospinal fluid analysis (elevated protein, low glucose, leukocytosis, gram-negative diplococci) are indicative of <strong>meningococcal meningitis</strong>; he subsequently developed septic shock (severe hypotension) while in the emergency department.&nbsp; His <strong>bleeding</strong> from venous puncture sites is highly suggestive of <strong>disseminated intravascular coagulation</strong> (DIC), a consumptive coagulopathy associated with <strong>sepsis</strong>, malignancy, trauma, and obstetric complications.</p><p>In DIC due to gram-negative sepsis, the coagulation cascade is activated by bacterial <strong>endotoxins</strong>, leading to widespread fibrin deposition and the consumption of coagulation factors and platelets, with eventual bleeding.&nbsp; Deposition of fibrin strands in small vessels can cause shearing of circulating erythrocytes, resulting in <a href=\"2939\">schistocytes</a> (fragmented erythrocytes) on peripheral smear.&nbsp; Laboratory values in DIC typically show <strong>decreased platelet count</strong> and fibrinogen level and <strong>prolonged PT and PTT</strong> (indicating a consumption of coagulation factors).</p><p><strong>(Choice A)</strong>&nbsp; <a href=\"244\">Atypical lymphocytes</a> are reactive lymphocytes with abundant, pale-blue cytoplasm and large nuclei.&nbsp; They are often seen in viral infections, particularly infectious mononucleosis.</p><p><strong>(Choice B)</strong>&nbsp; <a href=\"42519\">Howell-Jolly bodies</a> are round, dark, purple/red inclusions within erythrocytes.&nbsp; These represent nuclear fragments that are typically removed by the spleen; they can be seen in patients with splenectomy or reduced splenic function (eg, sickle cell).</p><p><strong>(Choice C)</strong>&nbsp; <a href=\"4341\">Hypersegmented neutrophils</a> are characterized by nuclei with &#8805;6 lobes.&nbsp; They are a feature of megaloblastic anemia (vitamin B<font size=\"2\"><sub>12</sub></font> or folate deficiency).</p><p><strong>(Choice D)</strong>&nbsp; Reactive thrombocytosis is common in infection due to cytokine-mediated megakaryocyte proliferation and the release of platelets into the peripheral bloodstream.&nbsp; In contrast, patients with DIC have thrombocytopenia due to platelet consumption.</p><p><strong>(Choice F)</strong>&nbsp; Severe pancytopenia is often seen in patients with aplastic anemia, which is characterized by destruction of hematopoietic stem cells and profoundly hypocellular bone marrow.&nbsp; Although patients with severe pancytopenia are at risk for bleeding, oozing from venipuncture sites in the setting of sepsis almost always indicates DIC.</p><p><strong>Educational objective:</strong><br>Disseminated intravascular coagulation is a common complication of gram-negative bacterial sepsis due to activation of the coagulation cascade by bacterial endotoxins, which leads to the formation of microthrombi.&nbsp; Peripheral smear shows fragmented erythrocytes (schistocytes) and thrombocytopenia.&nbsp; Laboratory tests show decreased fibrinogen levels and prolonged PT and PTT.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1295",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 57-year-old female presents to the emergency department after vomiting a substance that resembled &#x22;coffee grounds.&#x22;&nbsp; She reports that she now feels lightheaded as well.&nbsp; Her past medical history is significant for deep venous thromboses, for which she takes warfarin, and occasional joint pain, for which she takes aspirin.&nbsp; Her blood pressure is 90/60 mm Hg and her pulse is 110 beats per minute.&nbsp; Which of the following substances would provide the fastest reversal of warfarin&#39;s effects?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Vitamin K"
        },
        {
          "id": 2,
          "text": "Protamine"
        },
        {
          "id": 3,
          "text": "Aminocaproic acid"
        },
        {
          "id": 4,
          "text": "Fresh frozen plasma"
        },
        {
          "id": 5,
          "text": "Cryoprecipitate"
        },
        {
          "id": 6,
          "text": "Desmopressin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>Warfarin is the most commonly used agent for long-term anticoagulation in the setting of venous thromboses and pulmonary thromboembolism.&nbsp; Warfarin inhibits the vitamin K dependent <font face=\"Symbol\">g</font>-carboxylation of the glutamic acid residues of clotting factors II, VII, IX and X, causing production of dysfunctional coagulation proteins.</p><p>The therapeutic effect of warfarin is monitored by measuring the prothrombin time (PT).&nbsp; The international normalized ratio (INR) is a standardized PT.&nbsp; The target INR for therapeutic warfarin anticoagulation is 2-3.&nbsp; &nbsp;Bleeding is a common complication of warfarin therapy and the risk is increased with INRs above 3.0.&nbsp; Treatment of life-threatening bleeding requires rapid reversal using fresh frozen plasma.&nbsp; Vitamin K can help to reverse warfarin action, but the effects take time.</p><p><b>(Choice B)</b>&nbsp; Protamine is used for heparin reversal.&nbsp; It acts by binding and chemically inactivating heparin.</p><p><b>(Choice C)</b>&nbsp; Aminocaproic acid is an antifibrinolytic agent that inhibits plasminogen activators and, to a lesser degree, antiplasmin activity. &nbsp;Aminocaproic acid helps achieve hemostasis when fibrinolysis is the cause of bleeding.</p><p><b>(Choice E)</b>&nbsp; Whereas fresh frozen plasma contains all of the coagulation factors, cryoprecipitate contains only cold-soluble proteins (Factor VIII, fibrinogen, von Willebrand factor, and vitronectin).</p><p><b>(Choice F)</b>&nbsp; Desmopressin is a synthetic analogue of anti-diuretic hormone (ADH) used in the treatment of diabetes insipidus.&nbsp; At high doses, desmopressin increases factor VIII activity in patients with hemophilia A and von Willebrand disease.&nbsp; High-dose desmopressin can help control bleeding associated with these disorders.</p><p><b>Educational Objective:</b><br>Both vitamin K and fresh frozen plasma are used for reversing warfarin-induced anticoagulation.&nbsp; Fresh frozen plasma rapidly reverses warfarin&#39;s effects whereas vitamin K requires time for clotting factor re-synthesis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "709",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 61-year-old man comes to the hospital due to 2 days of right leg swelling.&nbsp; He recently flew back to the United States from Japan, where he was visiting his daughter who is spending a semester abroad.&nbsp; The patient has a medical history of hypertension and hyperlipidemia.&nbsp; Temperature is 37.2 C (99 F), blood pressure is 136/70 mm Hg, and pulse is 90/min.&nbsp; Pulse oximetry shows 99% on room air.&nbsp; Cardiopulmonary examination is within normal limits.&nbsp; There is tenderness and swelling of the right lower extremity up to the mid thigh.&nbsp; Laboratory studies, including prothrombin time and activated partial thromboplastin time, are normal.&nbsp; Venous doppler reveals an occluding thrombus in the right femoral and popliteal veins.&nbsp; The patient is started on rivaroxaban.&nbsp; This drug inhibits which of the following?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Factor VIII"
        },
        {
          "id": 2,
          "text": "Factor Xa"
        },
        {
          "id": 3,
          "text": "Glycoprotein IIb/IIIa"
        },
        {
          "id": 4,
          "text": "Platelet P2Y12"
        },
        {
          "id": 5,
          "text": "Thrombin"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Venous thromboembolism</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"672\" src=\"https://www.uworld.com/media/L4326.jpg\" ></p><p>This patient has right lower extremity proximal deep venous thrombosis (DVT), with his recent long flight from Japan being a possible risk factor.&nbsp; Many patients with DVT receive long-term anticoagulation with warfarin.&nbsp; Alternates include direct <strong>factor Xa</strong> inhibitors (eg, rivaro<strong>Xa</strong>ban, api<strong>Xa</strong>ban), which bind to the active site of factor Xa and prevent thrombin formation.&nbsp; These drugs can be administered orally as monotherapy and do not require laboratory monitoring.&nbsp; They are used for venous thromboembolism treatment as well as for stroke prophylaxis in patients with atrial fibrillation (who are at risk for embolic stroke).</p><p><strong>(Choice A)</strong>&nbsp; Factor VIII replacement (not inhibition) is the mainstay of hemophilia A treatment.</p><p><strong>(Choice C)</strong>&nbsp; Eptifibatide inhibits platelet aggregation and thrombosis by blocking the glycoprotein IIb/IIIa receptor, which is the binding site for fibrinogen.&nbsp; This drug is typically used in acute coronary syndrome and in patients undergoing percutaneous coronary intervention.</p><p><strong>(Choice D)</strong>&nbsp; Ticagrelor binds the adenosine diphosphate (ADP) P2Y12 receptor on platelets, which prevents platelet aggregation by blocking ADP-mediated activation of the glycoprotein IIb/IIIa receptor complex.&nbsp; This drug is also used in acute coronary syndrome and in patients undergoing percutaneous coronary intervention.</p><p><strong>(Choice E)</strong>&nbsp; Dabigatran is an oral direct thrombin inhibitor that inactivates both circulating and clot-associated thrombin.&nbsp; It is also used for treatment of thromboembolic disease and stroke prophylaxis in atrial fibrillation.</p><p><strong>Educational objective:</strong><br>Rivaroxaban is an oral anticoagulant that directly inhibits factor Xa.&nbsp; It is used in venous thromboembolism and atrial fibrillation.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "10625",
      "difficulty": "N/A"
    },
    {
      "text": "<p>An 18-year-old woman collapsed while practicing for a marathon in hot, humid weather.&nbsp; The patient subsequently vomited 3 times and had a tonic-clonic seizure.&nbsp; She has no chronic medical conditions and takes no medications.&nbsp; The patient does not use alcohol or illicit drugs.&nbsp; Temperature is 40.8 C (105.4 F), blood pressure is 90/60 mm Hg, pulse is 130/min, and respirations are 22/min.&nbsp; The patient is profusely sweating and is confused.&nbsp; Pupils are sluggishly reactive to light.&nbsp; Cardiopulmonary examination reveals clear lungs and normal heart sounds.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td colspan=\"2\">Complete blood count</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Hemoglobin</td><td>15.8 g/dL</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Platelets</td><td>90,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Leukocytes</td><td>10,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td colspan=\"2\"></td></tr><tr><td colspan=\"2\">Coagulation studies</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;PT</td><td>20 sec</td></tr><tr><td>&nbsp;&nbsp;&nbsp;&nbsp;Activated PTT</td><td>43 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Which of the following sets of hematologic findings is most likely to be present in this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;"
        },
        {
          "id": 2,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        },
        {
          "id": 3,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        },
        {
          "id": 4,
          "text": "&#8595;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;"
        },
        {
          "id": 5,
          "text": "&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;"
        },
        {
          "id": 6,
          "text": "&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8593;\n\t\t\t\n\t\t\t\n\t\t\t\t&#8595;"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > DIC</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This patient with extreme hyperthermia and seizures has <strong>exertional heat stroke</strong>, a life-threatening multisystem disorder caused by inadequate body heat dissipation.&nbsp; Severe hyperthermia increases tissue oxygen demand and metabolic rate and shunts blood away from the central organs (eg, brain, kidneys, liver, GI tract) to the skin to dissipate heat.&nbsp; This can lead to tissue ischemia/necrosis and the release of procoagulant proteins (eg, tissue factor), which can trigger <strong>disseminated intravascular coagulation</strong> (DIC).</p><p>DIC is marked by the excessive activation of the extrinsic (tissue factor) <a href=\"4730\">coagulation cascade</a>, leading to the <strong>generation of thrombin</strong> and cross-linked fibrin clots.&nbsp; <strong>Fibrinolysis is then activated</strong> to clear the intravascular thrombi; plasminogen is converted to <strong>plasmin</strong>, which cuts the cross-linked fibrin-fibers and generates fibrin-degradation products (eg, elevated D-dimer).&nbsp; Other anticoagulant proteins (eg, protein C, protein S) are also rapidly consumed.</p><p>Patients with acute DIC usually have bleeding (eg, oozing from venipuncture sites) and end organ damage (eg, confusion, lung injury, renal insufficiency); laboratory studies are diagnostic and show <strong>thrombocytopenia</strong> (due to consumption of platelets) and <strong>prolonged PT/PTT</strong> (due to consumption of coagulation factors).</p><p><strong>Educational objective:</strong><br>Disseminated intravascular coagulation is marked by widespread activation of the coagulation cascade, leading to excessive thrombin production and formation of microthrombi.&nbsp; Subsequent conversion of plasminogen to plasmin results in increased fibrinolysis to clear the thrombi.&nbsp; Laboratory studies show a consumption of clotting factors (prolonged PT/PTT) and platelets (thrombocytopenia) and signs of excessive fibrinolysis (eg, elevated D-dimer).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "15018",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 50-year-old woman comes to the emergency department due to a large, painful skin lesion.&nbsp; She does not remember sustaining any trauma.&nbsp; She was recently diagnosed with atrial fibrillation and started on treatment with warfarin.&nbsp; The patient noticed the lesion about a day and a half after starting the medication.&nbsp; Temperature is 36.7 C (98 F), blood pressure is 130/82 mm Hg, and pulse is 88/min and irregularly irregular.&nbsp; Physical examination findings are shown in the image below.</p><p><img draggable=\"false\" id=\"5338\" src=\"https://www.uworld.com/media/U15821.jpg\" ></p><p>The remainder of the skin examination is normal.&nbsp; Which of the following is the most likely cause of this patient&#39;s skin lesion?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Allergic drug reaction"
        },
        {
          "id": 2,
          "text": "Antithrombin deficiency"
        },
        {
          "id": 3,
          "text": "Autoimmune phenomena"
        },
        {
          "id": 4,
          "text": "Protein C deficiency"
        },
        {
          "id": 5,
          "text": "Vitamin K deficiency"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Atrial fibrillation</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p>This patient was started on warfarin to prevent thromboembolism secondary to atrial fibrillation.&nbsp; The sharply demarcated purpuric lesion likely represents <strong>warfarin-induced skin necrosis</strong>, a rare complication that results from an excessive decrease in protein C activity; patients with underlying <strong>protein C deficiency</strong> are at increased risk.</p><p>Protein C and S are innate anticoagulants that are vitamin K dependent, as are procoagulant factors II, VII, IX, and X.&nbsp; Warfarin inhibits <a href=\"3270\">epoxide reductase</a> (responsible for regenerating vitamin K), which leads to decreased levels of these proteins.&nbsp; Factor VII and <strong>protein C</strong> are <strong>depleted first</strong> due to their shorter half-life.&nbsp; The early loss of protein C activity relative to procoagulant factor activity leads to a <strong>transient hypercoagulable state</strong> that persists until the other procoagulant factors are <a href=\"45367\">sufficiently inhibited</a>.&nbsp; In patients with protein C deficiency, this procoagulant state is exaggerated, promoting <strong>microvasculature occlusion</strong> and hemorrhagic skin necrosis.&nbsp; Underlying protein S deficiency also increases the risk of warfarin-induced skin necrosis, though not to the same extent.</p><p>Treatment of warfarin-induced skin necrosis includes discontinuing warfarin and administering fresh frozen plasma or protein C concentrate.&nbsp; The condition may be prevented by the coadministration of heparin during the first several days of warfarin therapy.</p><p><strong>(Choice A)</strong>&nbsp; Allergic drug reactions are immune-mediated hypersensitivity reactions that can have variable cutaneous findings ranging from diffuse erythematous eruptions to extensive blistering and exfoliation (eg, Stevens-Johnson syndrome/toxic epidermal necrolysis); this patient&#39;s recent warfarin use and localized skin findings are more suggestive of warfarin-induced skin necrosis.</p><p><strong>(Choice B)</strong>&nbsp; Antithrombin deficiency can be inherited (autosomal dominant) or acquired (eg, cirrhosis, nephrotic syndrome) and presents with venous thromboembolism (eg, deep vein thrombosis, pulmonary embolism) and resistance to heparin.&nbsp; Warfarin does not affect antithrombin activity.</p><p><strong>(Choice C)</strong>&nbsp; Heparin-induced thrombocytopenia is an autoimmune phenomenon that causes arterial and venous thrombosis.&nbsp; It can produce skin findings similar to this patient&#39;s but would generally be associated with thrombocytopenia and recent heparin use.</p><p><strong>(Choice E)</strong>&nbsp; Vitamin K deficiency most often occurs in patients with fat malabsorption or those taking broad-spectrum antibiotics.&nbsp; The deficiency increases the inhibitory effect of warfarin on all vitamin K-dependent proteins (both anticoagulant and procoagulant), so it does not alter the relative coagulability balance to encourage warfarin-induced skin necrosis.</p><p><strong>Education objective:</strong><br>Patients started on warfarin develop a transient hypercoagulable state due to the short half-life of protein C.&nbsp; This hypercoagulability is further exaggerated by preexisting protein C deficiency and can result in thrombotic occlusion of the microvasculature with skin necrosis.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1292",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 16-year-old boy is brought to the emergency department due to nosebleeds and worsening bruising.&nbsp; He first noticed mild bruising on his lower legs a couple of days ago, and since then, the bruises have progressed along the thighs and hips.&nbsp; Today, he developed epistaxis that was difficult to control with applied pressure.&nbsp; The patient has Crohn disease and has had multiple hospitalizations for complications.&nbsp; He takes no anticoagulants.&nbsp; Vital signs are normal.&nbsp; Scant blood oozes from the nares.&nbsp; Abdominal examination is unremarkable, and pulses are strong.&nbsp; Skin examination shows large ecchymoses distributed along the lower extremities.&nbsp; Laboratory results are as follows:</p><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Platelets</td><td>230,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>PT</td><td>28 sec</td></tr><tr><td>Activated PTT</td><td>68 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Reversal of this patient&#39;s coagulation abnormalities is achieved with the intravenous administration of a medication.&nbsp; This treatment most likely directly affected which of the following cellular processes?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Epigenetic modification"
        },
        {
          "id": 2,
          "text": "Posttranscriptional modification"
        },
        {
          "id": 3,
          "text": "Posttranslational modification"
        },
        {
          "id": 4,
          "text": "Transcription"
        },
        {
          "id": 5,
          "text": "Translation"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Biochemistry > Hematology & Oncology > Vitamin k deficiency</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_t84202\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"2\"><p align=\"center\"><strong>Vitamin K deficiency</strong></p></td></tr><tr><td><p align=\"center\"><strong>Risk factors</strong></p></td><td><ul><li>Inadequate dietary intake (eg, malnutrition)</li><li>Fat malabsorption (eg, pancreatic insufficiency)</li><li>Intestinal inflammation (eg, inflammatory bowel disease)</li><li>&darr; Production by intestinal bacteria (eg, frequent antibiotics)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Pathophysiology</strong></p></td><td><ul><li>Impaired gamma-carboxylation of coagulation factors II, VII, IX &amp; X &rarr; &darr;&nbsp;factor activity</li></ul></td></tr><tr><td><p align=\"center\"><strong>Clinical features</strong></p></td><td><ul><li>Easy bruising</li><li>Mucosal bleeding</li></ul></td></tr><tr><td><p align=\"center\"><strong>Laboratory findings</strong></p></td><td><ul><li>&uarr; PT/INR</li><li>&uarr; PTT (if severe)</li></ul></td></tr><tr><td><p align=\"center\"><strong>Treatment</strong></p></td><td><ul><li>Vitamin K replacement</li></ul></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p>This patient with Crohn disease has epistaxis, bruising, and prolonged PT and PTT that are corrected with an intravenous medication.&nbsp; This presentation is consistent with <strong>vitamin K deficiency</strong>.&nbsp; Intestinal diseases associated with <strong>malabsorption</strong> (eg, inflammatory bowel disease [IBD]) are a risk factor for vitamin K deficiency.&nbsp; Infectious complications of IBD may also require frequent <strong>antibiotics</strong>, another possible contributing factor.</p><p>Vitamin K is a cofactor for <strong>gamma-glutamyl carboxylase</strong>, an enzyme required for the <strong>activation</strong> of coagulation<strong> </strong><strong>factors II</strong> (prothrombin), <strong>VII, IX, and X</strong>.&nbsp; These factors are produced in the <strong>liver</strong> as <a href=\"35655\">inactive forms</a>.&nbsp; The carboxylase enzyme converts glutamic acid residues to gamma-carboxyglutamic acid in the hepatocyte endoplasmic reticulum (ie, <strong>posttranslational carboxylation</strong>).&nbsp; Carboxylation allows the coagulation proteins to bind calcium ions in the blood and subsequently adhere to the platelet&#39;s negatively charged phospholipid bilayer, resulting in efficient coagulation.</p><p>Vitamin K deficiency leads to decreased coagulation factor activity, which predisposes to <strong>bruising</strong> and <strong>mucosal bleeding</strong>.&nbsp; Patients have <a href=\"466\">prolonged PT</a> and, in severe cases, <strong>PTT</strong>.&nbsp; Vitamin K replacement allows for carboxylation of vitamin K&ndash;dependent coagulation factors and reverses the coagulopathy.</p><p><strong>(Choice A)</strong>&nbsp; Some chemotherapeutic medications alter gene expression by affecting epigenetic modifications (eg, DNA methylation).&nbsp; Azacitidine, used to treat myelodysplastic syndrome, inhibits DNA methyltransferase, leading to hypomethylation and increased expression of tumor suppressor genes.</p><p><strong>(Choice B)</strong>&nbsp; RNA processing (posttranscriptional modification) includes 5&#8242; capping, polyadenylation, and splicing.&nbsp; Targeting splicing machinery is a new approach for treating several neoplastic/genetic diseases; for example, eteplirsen may be used to treat Duchenne muscular dystrophy.</p><p><strong>(Choice D)</strong>&nbsp; Certain chemotherapeutic agents (eg, dactinomycin, doxorubicin) interfere with transcription by intercalating in DNA, therefore preventing RNA synthesis.</p><p><strong>(Choice E)</strong>&nbsp; Asparaginase, used in the treatment of acute lymphoblastic leukemia/lymphoma, interferes with protein translation within the leukemic cells by reducing the amount of asparagine available.</p><p><strong>Educational objective:</strong><br>Vitamin K is a cofactor for gamma-glutamyl carboxylase, an enzyme that activates coagulation factors II, VII, IX, and X via posttranslational gamma carboxylation.&nbsp; Intestinal diseases associated with malabsorption (eg, inflammatory bowel disease) are a risk factor for vitamin K deficiency, which typically presents with mucosal bleeding, bruising, and prolonged PT and PTT (if severe).</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "22663",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 56-year-old man comes to the emergency department due to right lower extremity pain and swelling.&nbsp; The symptoms began shortly after he flew back to the United States from a 7-day cruise in Indonesia.&nbsp; Doppler ultrasonography reveals a femoropopliteal venous thrombosis, and the patient is given anticoagulation with rivaroxaban.&nbsp; Compared to vitamin K antagonists, this patient&#39;s treatment is most likely to have&nbsp;which of the following benefits?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Better patient compliance"
        },
        {
          "id": 2,
          "text": "Greater efficacy"
        },
        {
          "id": 3,
          "text": "Less risk of thrombocytopenia"
        },
        {
          "id": 4,
          "text": "No need for loading dose"
        },
        {
          "id": 5,
          "text": "Less variability in therapeutic effect"
        }
      ],
      "correct_choice_id": 5,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Anticoagulants</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><div id=\"div_T58959\"><table class=\"table-default-style\"><tbody><tr><td colspan=\"3\"><p align=\"center\"><strong>Direct oral anticoagulants (DOACs) versus warfarin</strong></p></td></tr><tr><td></td><td><p align=\"center\"><strong>DOACs</strong></p></td><td><p align=\"center\"><strong>Warfarin</strong></p></td></tr><tr><td><p align=\"center\"><strong>Dosing</strong></p></td><td><p align=\"center\">&gt;1 dose daily may be required</p></td><td><p align=\"center\">Once daily</p></td></tr><tr><td><p align=\"center\"><strong>Dietary restrictions</strong></p></td><td><p align=\"center\">None</p></td><td><p align=\"center\">Stable vitamin K intake required</p></td></tr><tr><td><p align=\"center\"><strong>Drug interactions</strong></p></td><td><p align=\"center\">Few</p></td><td><p align=\"center\">Many</p></td></tr><tr><td><p align=\"center\"><strong>Required monitoring</strong></p></td><td><p align=\"center\">None</p></td><td><p align=\"center\">INR</p></td></tr><tr><td><p align=\"center\"><strong>Comorbid conditions</strong></p></td><td><p align=\"center\">Renal failure may prohibit use</p></td><td><p align=\"center\">No prohibitions</p></td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></div><p><strong>Rivaroxaban</strong> is a direct oral anticoagulant (DOAC) that binds to and <strong>inhibits factor Xa</strong>, thereby preventing conversion of prothrombin to thrombin.&nbsp; DOACs are generally preferred over vitamin K antagonists (VKAs) such as warfarin for most conditions requiring prolonged anticoagulation due to <strong>less variability in therapeutic effect</strong>.</p><p>The therapeutic effect of VKAs is affected by changes to dietary intake of vitamin K, disruption to vitamin K&ndash; producing intestinal flora (eg, antibiotics), and a wide range of medications that inhibit or induce cytochrome P450 2C9; therefore, patients given VKAs require coagulation monitoring (eg, with INR) to ensure adequate anticoagulation.&nbsp; In contrast, the therapeutic effect of DOACs is not typically altered by environmental or medication changes; therefore, <strong>laboratory monitoring is not required</strong>.&nbsp; DOACs may also have a lower risk of intracranial bleeding, the most serious risk of anticoagulation, when compared to VKAs.</p><p><strong>(Choice A)</strong>&nbsp; Rates of patient compliance are roughly equivalent for DOACs and VKAs.</p><p><strong>(Choices B and C)</strong>&nbsp; Heparin can cause thrombocytopenia due to either heparin-induced thrombocytopenia type I (nonimmune mediated) or type 2 (immune mediated).&nbsp; VKAs target vitamin K&ndash;dependent clotting factors (not platelets), so they do not typically cause thrombocytopenia.&nbsp; VKAs and DOACs have roughly the same efficacy.</p><p><strong>(Choice D)</strong>&nbsp; A loading dose is required with heparin.&nbsp; Some DOACs (eg, rivaroxaban) also require a higher dose for the first few weeks prior to initiating a lower maintenance dose.&nbsp; VKAs do not require a loading dose.</p><p><strong>Educational objective:</strong><br>Direct oral anticoagulants (DOACs) such as rivaroxaban are often preferred over vitamin K antagonists (VKAs) such as warfarin in the treatment of conditions that require anticoagulation due to less variability in therapeutic drug effect; in contrast to VKAs, the efficacy of DOACs is unaffected by dietary changes and most medications.&nbsp; Therefore, patients given DOACs do not require laboratory monitoring.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "17234",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 24-year-old woman, gravida 1 para 0, at 14 weeks gestation, comes to the emergency department due to left leg swelling and pain for the past 2 days.&nbsp; She has had no chest pain or shortness of breath.&nbsp; The patient has no prior medical conditions and her only medication is a prenatal vitamin.&nbsp; She is a lifetime nonsmoker.&nbsp; Physical examination shows 1+ edema of the left lower extremity to the knee, associated with mild erythema.&nbsp; The left calf diameter measures 3 cm greater than the right.&nbsp; Doppler ultrasonography shows left popliteal and femoral vein thrombosis.&nbsp; Serum creatinine level is 0.7 mg/dL.&nbsp; Which of the following is the most appropriate pharmacotherapy for this patient?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Apixaban"
        },
        {
          "id": 2,
          "text": "Clopidogrel"
        },
        {
          "id": 3,
          "text": "Dabigatran"
        },
        {
          "id": 4,
          "text": "Enoxaparin"
        },
        {
          "id": 5,
          "text": "Low-dose aspirin"
        },
        {
          "id": 6,
          "text": "Tissue plasminogen activator"
        },
        {
          "id": 7,
          "text": "Warfarin"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pharmacology > Hematology & Oncology > Venous thromboembolism</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><strong>Pregnancy</strong> increases the risk of <strong>venous thromboembolism</strong> (VTE) due to anatomic changes (eg, uterine compression of the inferior vena cava and iliac veins) and physiologic hypercoagulability (eg, increased production of clotting factors, decreased protein S levels, protein C resistance).&nbsp; <strong>Heparins</strong> are ideal anticoagulants for most pregnant women as they do not cross the placenta and the risk of fetal bleeding and teratogenicity is low:</p><ul><li><p><strong>Low-molecular-weight heparin (LMWH)</strong> (eg, enoxaparin, dalteparin) is preferred as it has a relatively long half-life (4.5 hours) and does not require routine laboratory monitoring.&nbsp; However, it is renally cleared and cannot be used in patients with severe renal insufficiency (creatinine clearance &lt;30 mL/min).</p></li><li><p>Unfractionated heparin has a short half-life (1-2 hours) and requires frequent lab draws (ie, PTT) due to its more varied anticoagulant effect.&nbsp; However, it may be used in patients with renal insufficiency.&nbsp; It is also used in place of LMWH at term (37 weeks gestation) as it can be discontinued at the onset of labor to minimize hemorrhagic risk.</p></li></ul><p><strong>(Choices A and C)</strong>&nbsp; Direct thrombin inhibitors (eg, dabigatran) and factor Xa inhibitors (eg, apixaban) are not recommended in pregnant women.&nbsp; Both have been associated with fetal toxicity in animal studies.</p><p><strong>(Choices B and E)</strong>&nbsp; Clopidogrel and aspirin have no role in acute VTE treatment.&nbsp; Clopidogrel, which blocks the platelet adenosine diphosphate receptor and limits platelet aggregation, is used in treatment of coronary artery disease, acute coronary syndrome, and prevention of recurrent ischemic stroke.&nbsp; Low-dose aspirin is prescribed to certain pregnant patients at risk of preeclampsia.</p><p><strong>(Choice F)</strong>&nbsp; Recombinant tissue plasminogen activator is used for clot lysis.&nbsp; It has a high risk of major bleeding and is typically reserved for those with massive deep vein thrombosis at risk of limb ischemia or life-threatening pulmonary embolism with hypotension.&nbsp; Anticoagulation alone is preferred for VTE in hemodynamically stable patients.</p><p><strong>(Choice G)</strong>&nbsp; Warfarin crosses the placenta, increasing risks of teratogenicity and fetal hemorrhage, and is typically avoided in pregnancy.</p><p><strong>Educational objective:</strong><br>Heparins are ideal anticoagulants for most patients with thromboembolic disease in pregnancy as they do not cross the placenta and therefore the risk of fetal bleeding or teratogenicity is low.&nbsp; Low molecular weight heparin (eg, enoxaparin) is the preferred therapy, with patients transitioned to unfractionated heparin at term.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1194",
      "difficulty": "N/A"
    },
    {
      "text": "<p>A 50-year-old man with a long history of alcohol use disorder is admitted to the hospital with difficulty breathing.&nbsp; Blood pressure is 90/40 mm Hg, pulse is 114/min, respirations are 22/min, and pulse oximetry is 92% on room air.&nbsp; Physical examination shows bilateral basal crackles, increased jugular venous pressure, hepatomegaly, ascites, and peripheral pitting edema.&nbsp; Chest x-ray demonstrates cardiomegaly.&nbsp; Scattered ecchymoses are present across each extremity.&nbsp; Laboratory results are as follows:</p><blockquote><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\"><tbody><tr><td>Platelets</td><td>120,000/mm<font size=\"2\"><sup>3</sup></font></td></tr><tr><td>Prothrombin time</td><td>26 sec</td></tr><tr><td>Activated partial thromboplastin time</td><td>38 sec</td></tr></tbody></table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div></blockquote><p>The patient is given intramuscular vitamin K.&nbsp; Two days later, his laboratory results are unchanged.&nbsp; Which of the following is the most likely cause of this patient&#39;s laboratory abnormality?</p>",
      "choices": [
        {
          "id": 1,
          "text": "Dietary vitamin K deficiency"
        },
        {
          "id": 2,
          "text": "Factor VII deficiency"
        },
        {
          "id": 3,
          "text": "Factor VIII deficiency"
        },
        {
          "id": 4,
          "text": "Intrinsic platelet dysfunction"
        },
        {
          "id": 5,
          "text": "Von Willebrand factor deficiency"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<div style='margin-bottom:10px; font-size:0.85em; opacity:0.7;'>Pathophysiology > Hematology & Oncology > Cirrhosis</div><hr style='border-color:rgba(255,255,255,0.1); margin:10px 0;'><p><img draggable=\"false\" id=\"3269\" src=\"https://www.uworld.com/media/L25246.jpg\" ></p><p>This patient has <strong>liver dysfunction</strong> due to <strong>alcohol use disorder</strong>.&nbsp; The liver synthesizes many proteins, including <a href=\"466\">clotting factors</a>.&nbsp; Chronic alcohol use leads to progressive hepatic fibrosis/<strong>cirrhosis</strong>, resulting in acquired coagulopathy.</p><p><strong>Clotting factors II, VII, IX, and X</strong> are produced initially by the liver in an inactive form and then activated by <a href=\"3270\">vitamin K-dependent carboxylation</a>.&nbsp; <strong>Factor VII</strong>, part of the extrinsic pathway, has the <strong>shortest half-life</strong> of all coagulation factors.&nbsp; Prothrombin time (PT) assesses the extrinsic and common pathways of coagulation and is the first to become abnormal in liver disease.&nbsp; This patient&#39;s PT prolongation is likely due to factor VII deficiency in the setting of cirrhosis.&nbsp; Because clotting factor synthesis is impaired, PT may not improve with vitamin K supplementation as there are insufficient quantities of clotting factors to undergo vitamin K-dependent carboxylation/activation.</p><p>The liver also synthesizes albumin, and hypoalbuminemia results in ascites and peripheral edema.&nbsp; In addition, severe cirrhosis causes high-output heart failure due to chronic splanchnic vasodilation and development of mesenteric and intrahepatic arteriovenous shunts.</p><p><strong>(Choice A)</strong>&nbsp; Dietary vitamin K deficiency impairs activation of factors II, VII, IX, and X.&nbsp; Risk factors include severe malnourishment (eg, alcohol use disorder) and long-term antibiotic use (alters vitamin K-producing gut flora).&nbsp; In vitamin K deficiency, supplementation would likely improve PT.</p><p><strong>(Choice C)</strong>&nbsp; In contrast to other coagulation factors, factor VIII is synthesized by endothelial cells.&nbsp; As part of the intrinsic pathway, factor VIII deficiency results in prolonged activated partial thromboplastin time (PTT) with a normal PT.&nbsp; Hemophilia A is an X-linked recessive disorder of factor VIII deficiency.</p><p><strong>(Choice D)</strong>&nbsp; Cirrhosis is associated with intrinsic platelet dysfunction and thrombocytopenia due to decreased hepatic synthesis of thrombopoietin and increased splenic platelet sequestration (secondary to hypersplenism).&nbsp; Platelet dysfunction and significant thrombocytopenia (eg, platelets &lt;50,000/mm<font size=\"2\"><sup>3</sup></font>) lead to mucocutaneous bleeding/petechiae and prolonged bleeding time but do not affect PT.</p><p><strong>(Choice E)</strong>&nbsp; Von Willebrand disease causes defects in platelet adhesion and coagulation (due to associated factor VIII deficiency).&nbsp; PTT may be normal or prolonged based on the level of factor VIII deficiency, and platelet aggregation to ristocetin will be abnormal.</p><p><strong>Education objective:</strong><br>Vitamin K-dependent coagulation factors (II, VII, IX, and X) are synthesized in the liver.&nbsp; Factor VII has the shortest half-life of the coagulation factors.&nbsp; Failure of the prothrombin time to correct with vitamin K supplementation indicates factor VII deficiency, which is often due to underlying liver disease.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "1291",
      "difficulty": "N/A"
    }
  ]
}